Wireless re-charge of an implantable medical device

Description

TECHNICAL FIELD

The disclosure relates generally to implantable medical devices, and more particularly to implantable medical devices that have a power source that may be wirelessly recharged from a remote location such as from outside of the body.

BACKGROUND

Implantable medical devices are commonly used to perform a variety of functions, such as to monitor one or more conditions and/or delivery therapy to a patient. In some cases, an implantable medical device may deliver neurostimulation therapy to a patient. In some cases, an implantable medical device may simply monitor one or more conditions, such as pressure, acceleration, cardiac events, and may communicate the detected conditions or events to another device, such as another implantable medical device or an external programmer.

In some cases, an implantable medical device may be configured to deliver pacing and/or defibrillation therapy to a patient. Such implantable medical devices may treat patients suffering from various heart conditions that may result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. In some cases, heart conditions may lead to rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various devices (e.g., pacemakers, defibrillators, etc.) may be implanted into a patient's body. When so provided, such devices can monitor and provide therapy, such as electrical stimulation therapy, to the patient's heart to help the heart operate in a more normal, efficient and/or safe manner. In some cases, a patient may have multiple implanted devices that cooperate to monitor and/or provide therapy to the patient's heart.

Some implantable medical devices must be relatively small because of anatomical constraints. For example, leadless cardiac pacemakers are often placed within a heart chamber. Due to their relatively small size, and because of their long life expectancy, a large fraction of the internal space of such implantable medical devices is often consumed by a battery or other power source. As the battery life determines the useful life expectancy of the implantable medical device, there is a desire to make the batteries as large as possible within the confines of the available space.

What would be desirable is an implantable medical device that has recharge capability for recharging a rechargeable power source of the implantable medical device. This may give the implantable medical device a longer useful life expectancy and/or may not require as much battery space permitting a significantly smaller device size. A smaller device size may make the device more easily deliverable and implantable in the body, allow the device to be implantable in smaller and more confined spaces in the body, and/or may make the device less expensive to produce.

SUMMARY

The disclosure is directed to charging/recharging a power source of an implantable medical devices. While a leadless cardiac pacemaker is used as an example implantable medical device, it should be understood that the disclosure can be applied to any suitable implantable medical device including, for example, neuro-stimulators, diagnostic devices including those that do not deliver therapy, and/or any other suitable implantable medical device as desired.

In some cases, the disclosure pertains to a near-field energy transmitter for charging an implantable medical devices (IMD) such as leadless cardiac pacemakers (LCP) that include a rechargeable power source such as a rechargeable battery, a rechargeable capacitor or a rechargeable supercapacitor. In some cases, the transmitter may include an output drive that may drive a transmit coil such that the near-field energy is transmitted to the IMD at a determined frequency and amplitude. In some cases, the IMD may include a receiving coil that may capture the near-field energy and then convert the near-field energy into electrical energy that may be used to recharge the rechargeable power source. Accordingly, since the rechargeable power source does not have to maintain sufficient energy stores in a single charge for the entire expected lifetime of the IMD, the power source itself and thus the IMD may be made smaller while still meeting device longevity requirements.

In an example of the disclosure, a near-field energy transmitter for charging an IMD may include a transmit coil configured to transmit near-field energy to the IMD. An output driver may be configured for driving the transmit coil so that the transmit coil may transmit the near-field energy at a transmit frequency, wherein the transmit frequency may be adjustable. A monitor may be operatively coupled to the output driver and may detect a transmit power of the transmitted near-field energy. A controller may be operatively coupled to the output driver and the monitor and the controller may be configured to cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies, identify the transmit power of the near-field energy at each of the two or more transmit frequencies using the monitor, select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic, and set the transmit frequency of the output driver to the selected transmit frequency.

Alternatively or additionally to any of the embodiments above, the predetermined characteristic of the transmit power may be that the transmit power is the maximum transmit power identified for the two or more transmit frequencies.

Alternatively or additionally to any of the embodiments above, at least one of the transmit frequencies is a resonant frequency of the output driver and transmit coil, and the output driver includes an adjustable impedance that is adjustable to produce the resonance frequency.

Alternatively or additionally to any of the embodiments above, the controller may be configured to detect a decrease in the transmit power at the selected transmit frequency, and in response may cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies, identify the transmit power of the near-field energy at each of the two or more transmit frequencies, select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic, and set the transmit frequency of the output driver to the selected transmit frequency.

Alternatively or additionally to any of the embodiments above, the controller may be configured to repeat from time to time the following: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies, identify the transmit power of the near-field energy at each of the two or more transmit frequencies, select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic, and set the transmit frequency of the output driver to the selected transmit frequency.

Alternatively or additionally to any of the embodiments above, the near-field energy transmitter may further include a posture sensor for detecting a posture of a patient in which the implantable medical device is implanted, and wherein the controller may be configured to identify a transmit frequency for each of two or more postures by using the posture sensor to detect when the patient is in one of the two or more postures, and when in the detected posture, cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies, identify the transmit power of the near-field energy at each of the two or more transmit frequencies using the monitor, select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic, and associate the detected posture with the selected transmit frequency.

Alternatively or additionally to any of the embodiments above, the controller may be further configured to subsequently detect when the patient is in one of the two or more postures, and in response, set the transmit frequency of the output driver to the transmit frequency that is associated with the detected posture.

Alternatively or additionally to any of the embodiments above, the near-field energy transmitter may further include a communication block for communicating with the implantable medical device, and wherein the communication block may be configured to receive one or more messages from the implantable medical device regarding the transmit power that is received by the implantable medical device.

Alternatively or additionally to any of the embodiments above, the output driver may be configured to drive the transmit coil so that the transmit coil transmits the near-field energy at a transmit amplitude, wherein the transmit amplitude may be adjustable, and the controller may be configured to adjust the transmit amplitude of the near-field energy so that the transmit power that is received by the implantable medical device meets a predetermined characteristic, condition or criteria.

Alternatively or additionally to any of the embodiments above, the transmit coil may comprise a plurality of transmit coils and the output driver may be configured to drive the plurality of transmit coils so that the plurality of transmit coils may transmit the near-field energy along a transmit vector, wherein the transmit vector may be adjustable, and the controller may be configured to adjust the transmit vector of the near-field energy so that the transmit power that is received by the IMD may meet a predetermined criteria.

Alternatively or additionally to any of the embodiments above, the near-field energy transmitter may further include a flexible substrate configured to conform to a patient and house the transmitter coil.

Alternatively or additionally to any of the embodiments above, the flexible substrate may include a strap for securing the flexible substrate in place, and wherein the flexible substrate may have target fiducials to indicate a torso position of the patient relative to the transmit coil.

Alternatively or additionally to any of the embodiments above, the near-field energy transmitter may further include a ferromagnetic shield along a side of the transmit coil that may face away from the implantable medical device during use.

Alternatively or additionally to any of the embodiments above, the flexible substrate may be configured to be worn by the patient.

Alternatively or additionally to any of the embodiments above, the near-field energy transmitter may further include a second transmit coil housed by the flexible substrate, wherein the transmit coil may be configured to be located on a front of the patient and the second transmit coil may be configured to be located on a side or back of the patient.

Alternatively or additionally to any of the embodiments above, the controller may be further configured to issue a human perceptible alert if the transmit coil is deemed to be misaligned with the implantable medical device.

In another example of the disclosure, a near-field energy transmitter for charging an implantable medical device (IMD) may include a transmit coil that may be configured to transmit near-field energy to the implantable medical device. An output driver for driving the transmit coil may be provided. The output driver may cause the transmit coil to transmit the near-field energy at a transmit frequency and a transmit amplitude, wherein at least one of the transmit frequency and transmit amplitude may be adjustable. A communication block may be included for communicating with the implantable medical device. The communication block may be configured to receive one or more messages from the implantable medical device regarding the transmit power that is received by the implantable medical device. A controller may be operatively coupled to the output driver and the communication block. The controller may be configured to adjust one or more of the transmit frequency and transmit amplitude of the near-field energy so that the transmit power that is received by the implantable medical device may meet a predetermined characteristic, condition or criteria.

Alternatively or additionally to any of the embodiments above, the one or more messages received from the implantable medical device may indicate whether the transmit power that is received by the implantable medical device meets the predetermined characteristic, condition or criteria, and/or whether the transmit power that is received by the implantable medical device does and/or does not meet the predetermined characteristic, condition or criteria.

In another example of the disclosure, a near-field energy transmitter for chagrining an implantable medical device (IMD) may include one or more transmit coils that may be configured to transmit near-field energy to the IMD. An output driver that may drive the one or more transmit coils so that the one or more transmit coils may transmit the near-field energy at a transmit frequency, a transmit vector and a transmit amplitude, wherein at least one of the transmit frequency, transmit vector and transmit amplitude is adjustable, a communication block that may communicate with the IMD, wherein the communication block may be configured to receive one or more messages from the IMD regarding the transmit power that is received by the IMD, and a controller that may be operatively coupled to the output driver and the communication block, the controller may be configured to adjust one or more of the transmit frequency, the transmit vector and the transmit amplitude of the near-field energy so that the transmit power that is received by the IMD may meet a predetermined criteria.

In another example of the disclosure, an implantable medical device (IMD) may be configured to be implanted within a patient's body and may include a housing that may be configured for trans-catheter deployment. A plurality of electrodes that may be exposed external to the housing. Therapeutic circuitry that may be disposed within the housing and may be operatively coupled to the plurality of electrodes and may be configured to sense one or more signals via one or more of the plurality of electrodes and/or to stimulate tissue via one or more of the plurality of electrodes. A rechargeable power source may be disposed within the housing and may be configured to power the therapeutic circuitry. A receiving coil may be configured to receive non-radiative near-field energy through the patient's body. Charging circuitry may be operatively coupled with the receiving coil and the rechargeable power source and may be configured to use the non-radiative near-field energy received via the receiving coil to charge the rechargeable power source. A controller may be disposed within the housing and may be configured to detect whether the non-radiative near-field energy received by the receiving coil meets a predetermined characteristic, condition or criteria and communicate a message to a remotely located near-field energy transmitter indicating if the non-radiative near-field energy received by the receiving coil meets and/or does not meet the predetermined characteristic, condition or criteria.

BRIEF DESCRIPTION OF THE FIGURES

The disclosure may be more completely understood in consideration of the following description in connection with the accompanying drawings, in which:

FIG. 1 is a schematic block diagram of an illustrative LCP in accordance with an example of the disclosure;

FIG. 2 is a schematic block diagram of another illustrative medical device that may be used in conjunction with the LCP of FIG. 1;

FIG. 3 is a schematic diagram of an exemplary medical system that includes multiple LCPs and/or other devices in communication with one another;

FIG. 4 is a schematic diagram of a system including an LCP and another medical device, in accordance with an example of the disclosure;

FIG. 5 is a side view of an illustrative implantable leadless cardiac device;

FIG. 6 is a schematic diagram of a patient with a rechargeable implantable medical device system;

FIG. 7 is a schematic of an illustrative circuit for a coupled inductor system;

FIG. 8 is a schematic diagram of an illustrative implantable medical device (IMD) according to an example of the disclosure;

FIG. 9 is a schematic diagram of an illustrative transmitter according to an example of the disclosure;

FIG. 10 is a schematic diagram of another illustrative transmitter according to an example of the disclosure;

FIG. 11 is a schematic diagram of another illustrative transmitter according to an example of the disclosure;

FIG. 12 is a schematic diagram of another illustrative transmitter according to an example of the disclosure;

FIG. 13A provides a side-view of an illustration of a coil configuration for a near-field transmitter containing multiple transmit coils;

FIG. 13B provides a front-view of the illustration of the coil configuration for a near-field transmitter containing multiple transmit coils;

FIG. 14A is an illustrative flexible substrate that may house a transmit coil according to an example of the disclosure;

FIG. 14B is an illustrative flexible substrate, placed on a chair, that may house a transmit coil according to an example of the disclosure;

FIG. 14C is an illustrative flexible substrate, worn by a patient, that may house a transmit coil according to an example of the disclosure;

FIG. 15A is another illustrative flexible substrate that may house two transmit coils according to an example of the disclosure; and

FIG. 15B is an illustrative flexible substrate, worn by a patient, that may house two transmit coils according to an example of the disclosure.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DESCRIPTION

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.

All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.

The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include one or more particular features, structures, and/or characteristics. However, such recitations do not necessarily mean that all embodiments include the particular features, structures, and/or characteristics. Additionally, when particular features, structures, and/or characteristics are described in connection with one embodiment, it should be understood that such features, structures, and/or characteristics may also be used connection with other embodiments whether or not explicitly described unless clearly stated to the contrary.

The following description should be read with reference to the drawings in which similar structures in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure. While a leadless cardiac pacemaker is used as an example implantable medical device, it should be understood that the disclosure can be applied to any suitable implantable medical device including, for example, neuro-stimulators, diagnostic devices including those that do not deliver therapy, and/or any other suitable implantable medical device as desired.

FIG. 1 depicts an illustrative leadless cardiac pacemaker (LCP) that may be implanted into a patient and may operate to deliver appropriate therapy to the heart, such as to deliver anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), bradycardia therapy, and/or the like. As can be seen in FIG. 1, the LCP 100 may be a compact device with all components housed within the or directly on a housing 120. In some cases, the LCP 100 may be considered as being an example of an implantable medical device (IMD). In the example shown in FIG. 1, the LCP 100 may include a communication module 102, a pulse generator module 104, an electrical sensing module 106, a mechanical sensing module 108, a processing module 110, a battery 112, and an electrode arrangement 114. The LCP 100 may include more or less modules, depending on the application.

The communication module 102 may be configured to communicate with devices such as sensors, other medical devices such as an SICD, and/or the like, that are located externally to the LCP 100. Such devices may be located either external or internal to the patient's body. Irrespective of the location, external devices (i.e. external to the LCP 100 but not necessarily external to the patient's body) can communicate with the LCP 100 via communication module 102 to accomplish one or more desired functions. For example, the LCP 100 may communicate information, such as sensed electrical signals, data, instructions, messages, R-wave detection markers, etc., to an external medical device (e.g. SICD and/or programmer) through the communication module 102. The external medical device may use the communicated signals, data, instructions, messages, R-wave detection markers, etc., to perform various functions, such as determining occurrences of arrhythmias, delivering electrical stimulation therapy, storing received data, and/or performing any other suitable function. The LCP 100 may additionally receive information such as signals, data, instructions and/or messages from the external medical device through the communication module 102, and the LCP 100 may use the received signals, data, instructions and/or messages to perform various functions, such as determining occurrences of arrhythmias, delivering electrical stimulation therapy, storing received data, and/or performing any other suitable function. The communication module 102 may be configured to use one or more methods for communicating with external devices. For example, the communication module 102 may communicate via radiofrequency (RF) signals, inductive coupling, optical signals, acoustic signals, conducted communication signals, and/or any other signals suitable for communication.

In the example shown in FIG. 1, the pulse generator module 104 may be electrically connected to the electrodes 114. In some examples, the LCP 100 may additionally include electrodes 114′. In such examples, the pulse generator 104 may also be electrically connected to the electrodes 114′. The pulse generator module 104 may be configured to generate electrical stimulation signals. For example, the pulse generator module 104 may generate and deliver electrical stimulation signals by using energy stored in the battery 112 within the LCP 100 and deliver the generated electrical stimulation signals via the electrodes 114 and/or 114′. Alternatively, or additionally, the pulse generator 104 may include one or more capacitors, and the pulse generator 104 may charge the one or more capacitors by drawing energy from the battery 112. The pulse generator 104 may then use the energy of the one or more capacitors to deliver the generated electrical stimulation signals via the electrodes 114 and/or 114′. In at least some examples, the pulse generator 104 of the LCP 100 may include switching circuitry to selectively connect one or more of the electrodes 114 and/or 114′ to the pulse generator 104 in order to select which of the electrodes 114/114′ (and/or other electrodes) the pulse generator 104 delivers the electrical stimulation therapy. The pulse generator module 104 may generate and deliver electrical stimulation signals with particular features or in particular sequences in order to provide one or multiple of a number of different stimulation therapies. For example, the pulse generator module 104 may be configured to generate electrical stimulation signals to provide electrical stimulation therapy to combat bradycardia, tachycardia, cardiac synchronization, bradycardia arrhythmias, tachycardia arrhythmias, fibrillation arrhythmias, cardiac synchronization arrhythmias and/or to produce any other suitable electrical stimulation therapy. Some more common electrical stimulation therapies include anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), and cardioversion/defibrillation therapy. In some cases, the pulse generator 104 may provide a controllable pulse energy. In some cases, the pulse generator 104 may allow the controller to control the pulse voltage, pulse width, pulse shape or morphology, and/or any other suitable pulse characteristic.

In some examples, the LCP 100 may include an electrical sensing module 106, and in some cases, a mechanical sensing module 108. The electrical sensing module 106 may be configured to sense the cardiac electrical activity of the heart. For example, the electrical sensing module 106 may be connected to the electrodes 114/114′, and the electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through the electrodes 114/114′. The cardiac electrical signals may represent local information from the chamber in which the LCP 100 is implanted. For instance, if the LCP 100 is implanted within a ventricle of the heart (e.g. RV, LV), cardiac electrical signals sensed by the LCP 100 through the electrodes 114/114′ may represent ventricular cardiac electrical signals. In some cases, the LCP 100 may be configured to detect cardiac electrical signals from other chambers (e.g. far field), such as the P-wave from the atrium.

The mechanical sensing module 108 may include one or more sensors, such as an accelerometer, a pressure sensor, a heart sound sensor, a blood-oxygen sensor, a chemical sensor, a temperature sensor, a flow sensor and/or any other suitable sensors that are configured to measure one or more mechanical/chemical parameters of the patient. Both the electrical sensing module 106 and the mechanical sensing module 108 may be connected to a processing module 110, which may provide signals representative of the sensed mechanical parameters. Although described with respect to FIG. 1 as separate sensing modules, in some cases, the electrical sensing module 106 and the mechanical sensing module 108 may be combined into a single sensing module, as desired.

The electrodes 114/114′ can be secured relative to the housing 120 but exposed to the tissue and/or blood surrounding the LCP 100. In some cases, the electrodes 114 may be generally disposed on either end of the LCP 100 and may be in electrical communication with one or more of the modules 102, 104, 106, 108, and 110. The electrodes 114/114′ may be supported by the housing 120, although in some examples, the electrodes 114/114′ may be connected to the housing 120 through short connecting wires such that the electrodes 114/114′ are not directly secured relative to the housing 120. In examples where the LCP 100 includes one or more electrodes 114′, the electrodes 114′ may in some cases be disposed on the sides of the LCP 100, which may increase the number of electrodes by which the LCP 100 may sense cardiac electrical activity, deliver electrical stimulation and/or communicate with an external medical device. The electrodes 114/114′ can be made up of one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, the electrodes 114/114′ connected to the LCP 100 may have an insulative portion that electrically isolates the electrodes 114/114′ from adjacent electrodes, the housing 120, and/or other parts of the LCP 100. In some cases, one or more of the electrodes 114/114′ may be provided on a tail (not shown) that extends away from the housing 120.

The processing module 110 can be configured to control the operation of the LCP 100. For example, the processing module 110 may be configured to receive electrical signals from the electrical sensing module 106 and/or the mechanical sensing module 108. Based on the received signals, the processing module 110 may determine, for example, abnormalities in the operation of the heart H. Based on any determined abnormalities, the processing module 110 may control the pulse generator module 104 to generate and deliver electrical stimulation in accordance with one or more therapies to treat the determined abnormalities. The processing module 110 may further receive information from the communication module 102. In some examples, the processing module 110 may use such received information to help determine whether an abnormality is occurring, determine a type of abnormality, and/or to take particular action in response to the information. The processing module 110 may additionally control the communication module 102 to send/receive information to/from other devices.

In some examples, the processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip and/or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of the LCP 100. By using a pre-programmed chip, the processing module 110 may use less power than other programmable circuits (e.g. general purpose programmable microprocessors) while still being able to maintain basic functionality, thereby potentially increasing the battery life of the LCP 100. In other examples, the processing module 110 may include a programmable microprocessor. Such a programmable microprocessor may allow a user to modify the control logic of the LCP 100 even after implantation, thereby allowing for greater flexibility of the LCP 100 than when using a pre-programmed ASIC. In some examples, the processing module 110 may further include a memory, and the processing module 110 may store information on and read information from the memory. In other examples, the LCP 100 may include a separate memory (not shown) that is in communication with the processing module 110, such that the processing module 110 may read and write information to and from the separate memory.

The battery 112 may provide power to the LCP 100 for its operations. Because the LCP 100 is an implantable device, access to the LCP 100 may be limited after implantation. Accordingly, it is desirable to have sufficient battery capacity to deliver therapy over a period of treatment such as days, weeks, months, years or even decades. In some instances, the battery 112 may a rechargeable battery, which may help increase the useable lifespan of the LCP 100. In other examples, the battery 112 may be some other type of power source, as desired. In some cases, the battery 112 may not be battery at all, but rather may be super capacitor or other charge storage device. In some cases, the LCP 100 may include a receiver coil for receiving near-field energy. Charging circuitry may be operatively coupled with the receiving coil and the battery 112, and may be configured to use the non-radiative near-field energy received via the receiving coil to charge the battery 112.

To implant the LCP 100 inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix the LCP 100 to the cardiac tissue of the patient's heart. To facilitate fixation, the LCP 100 may include one or more anchors 116. The anchor 116 may include any one of a number of fixation or anchoring mechanisms. For example, the anchor 116 may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some examples, although not shown, the anchor 116 may include threads on its external surface that may run along at least a partial length of the anchor 116. The threads may provide friction between the cardiac tissue and the anchor to help fix the anchor 116 within the cardiac tissue. In other examples, the anchor 116 may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.

FIG. 2 depicts an example of another or second medical device (MD) 200, which may be used in conjunction with the LCP 100 (FIG. 1) in order to detect and/or treat cardiac abnormalities. In some cases, the MD 200 may be considered as an example of the IMD and/or the LCP. In the example shown, the MD 200 may include a communication module 202, a pulse generator module 204, an electrical sensing module 206, a mechanical sensing module 208, a processing module 210, and a battery 218. Each of these modules may be similar to the modules 102, 104, 106, 108, and 110 of LCP 100. Additionally, the battery 218 may be similar to the battery 112 of the LCP 100. In some examples, however, the MD 200 may have a larger volume within the housing 220. In such examples, the MD 200 may include a larger battery and/or a larger processing module 210 capable of handling more complex operations than the processing module 110 of the LCP 100.

While it is contemplated that the MD 200 may be another leadless device such as shown in FIG. 1, in some instances the MD 200 may include leads such as leads 212. The leads 212 may include electrical wires that conduct electrical signals between the electrodes 214 and one or more modules located within the housing 220. In some cases, the leads 212 may be connected to and extend away from the housing 220 of the MD 200. In some examples, the leads 212 are implanted on, within, or adjacent to a heart of a patient. The leads 212 may contain one or more electrodes 214 positioned at various locations on the leads 212, and in some cases at various distances from the housing 220. Some leads 212 may only include a single electrode 214, while other leads 212 may include multiple electrodes 214. Generally, the electrodes 214 are positioned on the leads 212 such that when the leads 212 are implanted within the patient, one or more of the electrodes 214 are positioned to perform a desired function. In some cases, the one or more of the electrodes 214 may be in contact with the patient's cardiac tissue. In some cases, the one or more of the electrodes 214 may be positioned subcutaneously and outside of the patient's heart. In some cases, the electrodes 214 may conduct intrinsically generated electrical signals to the leads 212, e.g. signals representative of intrinsic cardiac electrical activity. The leads 212 may, in turn, conduct the received electrical signals to one or more of the modules 202, 204, 206, and 208 of the MD 200. In some cases, the MD 200 may generate electrical stimulation signals, and the leads 212 may conduct the generated electrical stimulation signals to the electrodes 214. The electrodes 214 may then conduct the electrical signals and delivery the signals to the patient's heart (either directly or indirectly).

The mechanical sensing module 208, as with the mechanical sensing module 108, may contain or be electrically connected to one or more sensors, such as accelerometers, acoustic sensors, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which are configured to measure one or more mechanical/chemical parameters of the heart and/or patient. In some examples, one or more of the sensors may be located on the leads 212, but this is not required. In some examples, one or more of the sensors may be located in the housing 220.

While not required, in some examples, the MD 200 may be an implantable medical device. In such examples, the housing 220 of the MD 200 may be implanted in, for example, a transthoracic region of the patient. The housing 220 may generally include any of a number of known materials that are safe for implantation in a human body and may, when implanted, hermetically seal the various components of the MD 200 from fluids and tissues of the patient's body.

In some cases, the MD 200 may be an implantable cardiac pacemaker (ICP). In this example, the MD 200 may have one or more leads, for example the leads 212, which are implanted on or within the patient's heart. The one or more leads 212 may include one or more electrodes 214 that are in contact with cardiac tissue and/or blood of the patient's heart. The MD 200 may be configured to sense intrinsically generated cardiac electrical signals and determine, for example, one or more cardiac arrhythmias based on analysis of the sensed signals. The MD 200 may be configured to deliver CRT, ATP therapy, bradycardia therapy, and/or other therapy types via the leads 212 implanted within the heart. In some examples, the MD 200 may additionally be configured provide defibrillation therapy.

In some instances, the MD 200 may be an implantable cardioverter-defibrillator (ICD). In such examples, the MD 200 may include one or more leads implanted within a patient's heart. The MD 200 may also be configured to sense cardiac electrical signals, determine occurrences of tachyarrhythmias based on the sensed signals, and may be configured to deliver defibrillation therapy in response to determining an occurrence of a tachyarrhythmia. In other examples, the MD 200 may be a subcutaneous implantable cardioverter-defibrillator (S-ICD). In examples where the MD 200 is an S-ICD, one of the leads 212 may be a subcutaneously implanted lead. In at least some examples where the MD 200 is an S-ICD, the MD 200 may include only a single lead which is implanted subcutaneously, but this is not required. In some instances, the lead(s) may have one or more electrodes that are placed subcutaneously and outside of the chest cavity. In other examples, the lead(s) may have one or more electrodes that are placed inside of the chest cavity, such as just interior of the sternum but outside of the heart H.

In some examples, the MD 200 may not be an implantable medical device. Rather, the MD 200 may be a device external to the patient's body, and may include skin-electrodes that are placed on a patient's body. In such examples, the MD 200 may be able to sense surface electrical signals (e.g. cardiac electrical signals that are generated by the heart or electrical signals generated by a device implanted within a patient's body and conducted through the body to the skin). In such examples, the MD 200 may be configured to deliver various types of electrical stimulation therapy, including, for example, defibrillation therapy.

In some cases, the MD 200 may be external to the patient's body and may include a transmit coil that is configured to transmit near-field energy to an implanted IMD. The MD 200 may also include an output driver for driving the transmit coil at a transmit frequency and a transmit amplitude. The transmit frequency and/or transmit amplitude may be tuned, sometimes actively tuned, so as to deliver an acceptable transmit power to a receive coil of the implanted IMD. The transmit power may be used to recharge a power source of the implanted IMD.

FIG. 3 illustrates an example of a medical device system and a communication pathway through which multiple medical devices 302, 304, 306, and/or 310 may communicate. In the example shown, the medical device system 300 may include LCPs 302 and 304, external medical device 306, and other sensors/devices 310. The external device 306 may be any of the devices described previously with respect to the MD 200. Other sensors/devices 310 may also be any of the devices described previously with respect to the MD 200. In some instances, other sensors/devices 310 may include a sensor, such as an accelerometer, an acoustic sensor, a blood pressure sensor, or the like. In some cases, other sensors/devices 310 may include an external programmer device that may be used to program one or more devices of the system 300.

Various devices of the system 300 may communicate via communication pathway 308. For example, the LCPs 302 and/or 304 may sense intrinsic cardiac electrical signals and may communicate such signals to one or more other devices 302/304, 306, and 310 of the system 300 via communication pathway 308. In one example, one or more of the devices 302/304 may receive such signals and, based on the received signals, determine an occurrence of an arrhythmia. In some cases, the device or devices 302/304 may communicate such determinations to one or more other devices 306 and 310 of the system 300. In some cases, one or more of the devices 302/304, 306, and 310 of the system 300 may take action based on the communicated determination of an arrhythmia, such as by delivering a suitable electrical stimulation to the heart of the patient. It is contemplated that the communication pathway 308 may communicate using RF signals, inductive coupling, optical signals, acoustic signals, or any other signals suitable for communication. Additionally, in at least some examples, communication pathway 308 may include multiple signal types. For instance, other sensors/device 310 may communicate with the external device 306 using a first signal type (e.g. RF communication) but communicate with the LCPs 302/304 using a second signal type (e.g. conducted communication). Further, in some examples, communication between devices may be limited. For instance, as described above, in some examples, the LCPs 302/304 may communicate with the external device 306 only through other sensors/devices 310, where the LCPs 302/304 send signals to other sensors/devices 310, and other sensors/devices 310 relay the received signals to the external device 306.

In some cases, the communication pathway 308 may include conducted communication. Accordingly, devices of the system 300 may have components that allow for such conducted communication. For instance, the devices of system 300 may be configured to transmit conducted communication signals (e.g. current and/or voltage pulses) into the patient's body via one or more electrodes of a transmitting device, and may receive the conducted communication signals (e.g. pulses) via one or more electrodes of a receiving device. The patient's body may “conduct” the conducted communication signals (e.g. pulses) from the one or more electrodes of the transmitting device to the electrodes of the receiving device in the system 300. In such examples, the delivered conducted communication signals (e.g. pulses) may differ from pacing or other therapy signals. For example, the devices of the system 300 may deliver electrical communication pulses at an amplitude/pulse width that is sub-capture threshold to the heart. Although, in some cases, the amplitude/pulse width of the delivered electrical communication pulses may be above the capture threshold of the heart, but may be delivered during a blanking period of the heart (e.g. refractory period) and/or may be incorporated in or modulated onto a pacing pulse, if desired.

Delivered electrical communication pulses may be modulated in any suitable manner to encode communicated information. In some cases, the communication pulses may be pulse width modulated or amplitude modulated. Alternatively, or in addition, the time between pulses may be modulated to encode desired information. In some cases, conducted communication pulses may be voltage pulses, current pulses, biphasic voltage pulses, biphasic current pulses, or any other suitable electrical pulse as desired. Alternatively, or in addition, the communication pathway 308 may include radiofrequency (RF) communication, inductive communication, optical communication, acoustic communication and/or any other suitable communication, as desired.

FIG. 4 shows an illustrative medical device system. In FIG. 4, an LCP 402 is shown fixed to the interior of the left ventricle of the heart 410, and a pulse generator 406 is shown coupled to a lead 412 having one or more electrodes 408a-408c. In some cases, the pulse generator 406 may be part of a subcutaneous implantable cardioverter-defibrillator (S-ICD), and the one or more electrodes 408a-408c may be positioned subcutaneously. In some cases, the one or more electrodes 408a-408c may be placed inside of the chest cavity but outside of the heart, such as just interior of the sternum.

In some cases, the LCP 402 may communicate with the subcutaneous implantable cardioverter-defibrillator (S-ICD). In some cases, the lead 412 and/or pulse generator 406 may include an accelerometer 414 that may, for example, be configured to sense vibrations that may be indicative of heart sounds.

In some cases, the LCP 402 may be in the right ventricle, right atrium, left ventricle or left atrium of the heart, as desired. In some cases, more than one LCP 402 may be implanted. For example, one LCP may be implanted in the right ventricle and another may be implanted in the right atrium. In another example, one LCP may be implanted in the right ventricle and another may be implanted in the left ventricle. In yet another example, one LCP may be implanted in each of the chambers of the heart.

FIG. 5 is a side view of an illustrative implantable leadless cardiac pacemaker (LCP) 610. The LCP 610 may be similar in form and function to the LCP 100 described above. The LCP 610 may include any of the modules and/or structural features described above with respect to the LCP 100 described above. The LCP 610 may include a shell or housing 612 having a proximal end 614 and a distal end 616. The illustrative LCP 610 includes a first electrode 620 secured relative to the housing 612 and positioned adjacent to the distal end 616 of the housing 612 and a second electrode 622 secured relative to the housing 612 and positioned adjacent to the proximal end 614 of the housing 612. In some cases, the housing 612 may include a conductive material and may be insulated along a portion of its length. A section along the proximal end 614 may be free of insulation so as to define the second electrode 622. The electrodes 620, 622 may be sensing and/or pacing electrodes to provide electro-therapy and/or sensing capabilities. The first electrode 620 may be capable of being positioned against or may otherwise contact the cardiac tissue of the heart while the second electrode 622 may be spaced away from the first electrode 620. The first and/or second electrodes 620, 622 may be exposed to the environment outside the housing 612 (e.g. to blood and/or tissue).

In some cases, the LCP 610 may include a pulse generator (e.g., electrical circuitry) and a power source (e.g., a battery) within the housing 612 to provide electrical signals to the electrodes 620, 622 to control the pacing/sensing electrodes 620, 622. While not explicitly shown, the LCP 610 may also include, a communications module, an electrical sensing module, a mechanical sensing module, and/or a processing module, and the associated circuitry, similar in form and function to the modules 102, 106, 108, 110 described above. The various modules and electrical circuitry may be disposed within the housing 612. Electrical connections between the pulse generator and the electrodes 620, 622 may allow electrical stimulation to heart tissue and/or sense a physiological condition.

In the example shown, the LCP 610 includes a fixation mechanism 624 proximate the distal end 616 of the housing 612. The fixation mechanism 624 is configured to attach the LCP 610 to a wall of the heart H, or otherwise anchor the LCP 610 to the anatomy of the patient. In some instances, the fixation mechanism 624 may include one or more, or a plurality of hooks or tines 626 anchored into the cardiac tissue of the heart H to attach the LCP 610 to a tissue wall. In other instances, the fixation mechanism 624 may include one or more, or a plurality of passive tines, configured to entangle with trabeculae within the chamber of the heart H and/or a helical fixation anchor configured to be screwed into a tissue wall to anchor the LCP 610 to the heart H. These are just examples.

The LCP 610 may further include a docking member 630 proximate the proximal end 614 of the housing 612. The docking member 630 may be configured to facilitate delivery and/or retrieval of the LCP 610. For example, the docking member 630 may extend from the proximal end 614 of the housing 612 along a longitudinal axis of the housing 612. The docking member 630 may include a head portion 632 and a neck portion 634 extending between the housing 612 and the head portion 632. The head portion 632 may be an enlarged portion relative to the neck portion 634. For example, the head portion 632 may have a radial dimension from the longitudinal axis of the LCP 610 that is greater than a radial dimension of the neck portion 634 from the longitudinal axis of the LCP 610. In some cases, the docking member 630 may further include a tether retention structure 636 extending from or recessed within the head portion 632. The tether retention structure 636 may define an opening 638 configured to receive a tether or other anchoring mechanism therethrough. While the retention structure 636 is shown as having a generally “U-shaped” configuration, the retention structure 636 may take any shape that provides an enclosed perimeter surrounding the opening 638 such that a tether may be securably and releasably passed (e.g. looped) through the opening 638. In some cases, the retention structure 636 may extend though the head portion 632, along the neck portion 634, and to or into the proximal end 614 of the housing 612. The docking member 630 may be configured to facilitate delivery of the LCP 610 to the intracardiac site and/or retrieval of the LCP 610 from the intracardiac site. While this describes one example docking member 630, it is contemplated that the docking member 630, when provided, can have any suitable configuration.

It is contemplated that the LCP 610 may include one or more pressure sensors 640 coupled to or formed within the housing 612 such that the pressure sensor(s) is exposed to the environment outside the housing 612 to measure blood pressure within the heart. For example, if the LCP 610 is placed in the left ventricle, the pressure sensor(s) 640 may measure the pressure within the left ventricle. If the LCP 610 is placed in another portion of the heart (such as one of the atriums or the right ventricle), the pressures sensor(s) may measure the pressure within that portion of the heart. The pressure sensor(s) 640 may include a MEMS device, such as a MEMS device with a pressure diaphragm and piezoresistors on the diaphragm, a piezoelectric sensor, a capacitor-Micro-machined Ultrasonic Transducer (cMUT), a condenser, a micro-monometer, or any other suitable sensor adapted for measuring cardiac pressure. The pressures sensor(s) 640 may be part of a mechanical sensing module described herein. It is contemplated that the pressure measurements obtained from the pressures sensor(s) 640 may be used to generate a pressure curve over cardiac cycles. The pressure readings may be taken in combination with impedance measurements (e.g. the impedance between electrodes 620 and 622) to generate a pressure-impedance loop for one or more cardiac cycles as will be described in more detail below. The impedance may be a surrogate for chamber volume, and thus the pressure-impedance loop may be representative for a pressure-volume loop for the heart H.

In some embodiments, the LCP 610 may be configured to measure impedance between the electrodes 620, 622. More generally, the impedance may be measured between other electrode pairs, such as the additional electrodes 114′ described above. In some cases, the impedance may be measure between two spaced LCP's, such as two LCP's implanted within the same chamber (e.g. LV) of the heart H, or two LCP's implanted in different chambers of the heart H (e.g. RV and LV). The processing module of the LCP 610 and/or external support devices may derive a measure of cardiac volume from intracardiac impedance measurements made between the electrodes 620, 622 (or other electrodes). Primarily due to the difference in the resistivity of blood and the resistivity of the cardiac tissue of the heart H, the impedance measurement may vary during a cardiac cycle as the volume of blood (and thus the volume of the chamber) surrounding the LCP changes. In some cases, the measure of cardiac volume may be a relative measure, rather than an actual measure. In some cases, the intracardiac impedance may be correlated to an actual measure of cardiac volume via a calibration process, sometimes performed during implantation of the LCP(s). During the calibration process, the actual cardiac volume may be determined using fluoroscopy or the like, and the measured impedance may be correlated to the actual cardiac volume.

In some cases, the LCP 610 may be provided with energy delivery circuitry operatively coupled to the first electrode 620 and the second electrode 622 for causing a current to flow between the first electrode 620 and the second electrode 622 in order to determine the impedance between the two electrodes 620, 622 (or other electrode pair). It is contemplated that the energy delivery circuitry may also be configured to deliver pacing pulses via the first and/or second electrodes 620, 622. The LCP 610 may further include detection circuitry operatively coupled to the first electrode 620 and the second electrode 622 for detecting an electrical signal received between the first electrode 620 and the second electrode 622. In some instances, the detection circuitry may be configured to detect cardiac signals received between the first electrode 620 and the second electrode 622.

When the energy delivery circuitry delivers a current between the first electrode 620 and the second electrode 622, the detection circuitry may measure a resulting voltage between the first electrode 620 and the second electrode 622 (or between a third and fourth electrode separate from the first electrode 620 and the second electrode 622, not shown) to determine the impedance. When the energy delivery circuitry delivers a voltage between the first electrode 620 and the second electrode 622, the detection circuitry may measure a resulting current between the first electrode 620 and the second electrode 622 (or between a third and fourth electrode separate from the first electrode 620 and the second electrode 622) to determine the impedance.

FIG. 6 provides a highly schematic illustration of a patient 700 having an implantable device (IMD) 702 implanted within the patient 700. While the IMD 702 is shown as being in or near the patient's chest, it will be appreciated that this is merely illustrative, as the IMD 702, depending on functionality, may be implanted in other locations within the patient 700. A transmitter 704 is shown exterior to the patient 700. In some cases, the transmitter 704 may be configured to transmit reactive near-field energy that is of a wavelength (or frequency, as wavelength and frequency are related by the numerical speed of light) and amplitude that can safety pass into the patient 700 to the IMD 702 without causing excessive tissue heating or other potentially damaging effects to the patient 700.

The transmitter 704 may take any suitable form. For example, while shown schematically as a box in FIG. 6, the transmitter 704 may be sized and configured for the patient 700 to periodically wear about their neck on a lanyard or in a shirt pocket, which would place the transmitter 704 proximate their chest, at about the same vertical and horizontal position as the IMD 702 within the patient's chest. In some cases, the transmitter 704 may be built into the back of a chair that the patient 700 would periodically sit in to recharge the IMD 702. The chair could be in the patient's home, for a daily recharge, for example, or could be at a remote location such as a medical clinic, for a patient 700 having a longer recharge schedule.

As another example, the transmitter 704 could be built into a bed such that the transmitter 704 could at least partially recharge the IMD 702 each evening when the patient 700 sleeps. In some cases, the transmitter 704 could be configured to only transmit once per week, or once per month, for example, depending on the power requirements of the IMD 702. In some cases, the transmitter 704 and the IMD 702 may communicate with each other. When so provided, the IMD 702 may report its current battery recharge level to the transmitter 704, and if the current battery recharge level is below a threshold, the transmitter 704 may transmit power to the IMD 702.

It will be appreciated that the IMD 702 may be configured to periodically receive near-field energy at a wavelength and intensity that is safe for the patient 700 and that the IMD 702 may use to recharge a rechargeable power source within the IMD 702. The near-field energy may be received at a rate that exceeds a rate at which power is being drawn from the rechargeable battery and consumed by various components within the IMD 702.

FIG. 7 provides an illustrative circuit for a coupled inductor system 800. Inductive coupling is the near-field wireless transmission of electrical energy between a source 802 and a device 804. In some cases, the source 802 may transfer power from a source inductor 806 (e.g. source coil) to a device inductor 808 (e.g. device coil) by a magnetic field. The system 800, therefore, may act as a transformer. In some cases, a signal generator 810 may generate an alternating current (AC) through the source inductor 806 and create an oscillating magnetic field. The signal generator 810 may include an output driver. The magnetic field may pass through the device inductor 808 and induce an alternating electromagnetic force (EMF), which creates an alternating current (AC) in the device 804. The induced AC may either drive a load 812 directly, or be rectified to direct current (DC) by a rectifier (not shown) in the device 804, which drives the load 812.

In some cases, the power transferred may increase with frequency and mutual inductance between the source inductor 806 and the device inductor 808, which may depend on their geometry and the distance between them. For example, if the source inductor 806 and the device inductor 808 are on the same axis (i.e., a primary capture axis) and close together so the magnetic flux from the source inductor 806 passes through the device inductor 808, the transfer of power may approach 100%. The greater the separation between the coils, the more the magnetic flux from the source inductor 806 may miss the device inductor 808, and the transfer of power may decrease.

In some cases, the source inductor 806 and/or the device inductor 808 may be fitted with magnetic cores. A magnetic core can be a piece of magnetically active material with a high magnetic permeability used to confine and guide magnetic fields in electrical, electromechanical and magnetic devices such as electromagnets, transformers, generators, inductors, and other magnetic assemblies. In some cases, the magnetic core may be made of ferromagnetic metal such as iron, or ferromagnetic compounds such as ferrites. The high permeability, relative to the surrounding atmosphere, may cause the magnetic field lines to be concentrated in the ferrite core. In some cases, the use of the ferrite core can concentrate the strength and increase the effect of magnetic fields produced by the source inductor 806 and may improve inductive coupling and the transfer of power.

In some cases, the system may achieve resonant inductive coupling. In this case, the source 802 can be tuned to resonant at the same frequency as the device 804. In some cases, the source 802 can include the source inductor 806 connected to a capacitor 814. The resonance between the source inductor 806 and the device inductor 808 can increase the coupling and the transmitted power. In some cases, when the system 800 achieves resonant inductive coupling, the source 802 and the device 804 may interact with each other more strongly than they do with non-resonant objects and power losses due to absorption in stray nearby objects may be reduced.

FIG. 8 provides a cross-sectional view of the illustrative IMD 702. In some cases, the IMD 702 includes a device housing 706 that may encompass a receiving coil 708, charging circuitry 710, a rechargeable power source 712, therapeutic circuitry 714, and a controller 717. In various embodiments, the housing 706 may have a proximal end 716 and a distal end 718. The IMD 702 may include a first electrode 715 positioned adjacent to the distal end 718 of the housing 706 and a second electrode 719 positioned adjacent to the proximal end 716 of the housing 706. In some cases, the housing 706 may include a conductive material and may be insulated along a portion of its length. A section along the proximal end 716 may be free of insulation so as to define the second electrode 719. This is just one example implementation. The electrodes 715, 719 may be sensing and/or pacing electrodes to provide electro-therapy and/or sensing capabilities. The first electrode 715 may be capable of being positioned against or may otherwise contact cardiac tissue of a heart while the second electrode 719 may be spaced away from the first electrode 715, and thus spaced away from the cardiac tissue.

The illustrative IMD 702 may include a fixation mechanism 720 proximate the distal end 718 of the housing 706, which may be configured to attach the IMD 702 to a tissue wall of the heart, or otherwise anchor the IMD 702 to the anatomy of the patient. As shown in FIG. 8, in some instances, the fixation mechanism 720 may include one or more, or a plurality of hooks or tines anchored into the cardiac tissue of the heart to attach the IMD 702 to the tissue wall. In other instances, the fixation mechanism 720 may include one or more, or a plurality of passive tines, configured to entangle with trabeculae within the chamber of the heart and/or a helical fixation anchor configured to be screwed into the tissue wall to anchor the IMD 702 to the heart.

In some cases, the IMD 702 may include a docking member 722 proximate the proximal end 716 of the housing 706 configured to facilitate delivery and/or retrieval of the IMD 702. For example, the docking member 722 may extend from the proximal end 716 of the housing 706 along a longitudinal axis of the housing 706. The docking member 722 may include a head portion 724 and a neck portion 726 extending between the housing 706 and the head portion 724. The head portion 724 may be an enlarged portion relative to the neck portion 726. For example, the head portion 724 may have a radial dimension from the longitudinal axis of the IMD 702 which is greater than a radial dimension of the neck portion 726 from the longitudinal axis of the IMD 702. The docking member 722 may further include a tether retention structure 728 extending from the head portion 724. The tether retention structure 728 may define an opening 730 configured to receive a tether or other anchoring mechanism therethrough. While the retention structure 728 is shown as having a generally “U-shaped” configuration, the retention structure 728 may take any shape which provides an enclosed perimeter surrounding the opening 730 such that a tether may be securably and releasably passed (e.g. looped) through the opening 730. The retention structure 728 may extend though the head portion 724, along the neck portion 726, and to or into the proximal end 716 of the housing 706. The docking member 722 may be configured to facilitate delivery of the IMD 702 to the intracardiac site and/or retrieval of the IMD 702 from the intracardiac site. Other docking members 722 are contemplated.

According to various embodiments, the housing may also be configured for trans-catheter deployment. In some cases, this means that the housing 706 has overall dimensions that enable the IMD 702 to fit within a catheter or similar device for delivering the IMD 702 via a vascular approach. In some cases, the housing 706 may have an overall length of perhaps about 50 millimeters or less, or perhaps about 30 millimeters or less, and/or an overall width of perhaps about 20 millimeters or less, or perhaps about 10 millimeters or less. These are just examples.

In some cases, the receiving coil 708 may be any of a variety of different types of coils. When considering the electromagnetic regions around a transmitting coil/antenna, there are three categories; namely, (1) reactive near-field; (2) radiated near-field and (3) radiated far-field. “Inductive” charging systems operate in the reactive near-field region. In inductive power systems, power is typically transferred over short distances by magnetic fields using inductive coupling between coils of wire, such as receiving coil 708 or by electric fields using capacitive coupling between electrodes. In radiative power systems (e.g. radiated near-field and radiated far-field), power is typically transmitted by beams of electromagnetic (EM) energy. Radiative power systems can often transport energy for longer distances, but the ability of a receiving antenna to capture sufficient energy can be challenging, particular for applications where the size of the receiving antenna is limited.

In some cases, a transmitter (such as transmitter 704 of FIG. 6) and IMD 702 may operate between 10 kHz and 100 MHz within the patient's body. When so provided, the system may operate in the reactive near-field (as an inductive charging system). In some cases, the transmitter 704 may transmit the near-field energy such that a receiving coil (i.e., receiving coil 708) may capture the near-field energy and provide it to the charging circuitry 710. In some cases, the charging circuitry 710 may be configured to convert the received near-field energy into a form that may be used to recharge the rechargeable power source 712. In some cases, the receiving coil 708 may be configured to receive sufficient near-field energy from a wavelength band of near-field energy transmitted from outside the patient 700 (FIG. 6) to recharge the rechargeable power source 712 at a rate faster than the rechargeable power source 712 is depleted by powering the IMD 702 when the wavelength band of near-field energy is transmitted at an intensity that does not cause heat damage to the patient 700. In various embodiments, the IMD 702 may include a temperature sensor (not shown) that may be configured to determine if self-heating of the IMD 702 is occurring when the rechargeable power source 712 is charging. In some cases, the housing 706 of the IMD 702 has a substantially cylindrical profile and the receiving coil 708 may be conformed to the substantially cylindrical profile of an inner and/or outer surface of the housing 706. In some cases, there may be two or more coils within or on the IMD 702. For example, two or more coils may be placed inside the housing 706. In some cases, there may be three coils oriented orthogonal to one another.

The rechargeable power source 712 may be any type of rechargeable battery, and may take a three dimensional shape that facilitates incorporation of the rechargeable battery into the device housing 706. In some cases, the rechargeable power source 712 may not be a battery at all, but instead may be a super capacitor, other charge storage device or combination of different types of energy storage devices. As will be appreciated, in some cases the device housing 706 may have a cylindrical or substantially cylindrical shape, in which case the rechargeable power source 712 having a cylindrical or annular profile, such as a button battery or an elongated (in height) battery having a substantially cylindrical shape, may be useful. It is recognized that there are possible tradeoffs in rechargeable battery shape and dimensions relative to performance, so these issues should be considered in designing the rechargeable power source 712 for a particular use. While FIG. 8 schematically shows a single rechargeable power source 712, in some cases there may be two, three or more distinct rechargeable power sources 712, each electrically coupled with the charging circuitry 710. For example, in some cases, there may be performance advantages in having multiple rechargeable power sources 712. In some instances, there may be packaging advantages to having multiple (and smaller) rechargeable power sources 712.

In some cases, the rechargeable power source 712 may be configured to power the IMD 702, including the therapeutic circuitry 714. In some instances, the therapeutic circuitry 714 and the rechargeable power source 712 may provide electrical signals to the electrodes 715, 719 and thus control the pacing/sensing electrodes 715, 719. In some instances, the therapeutic circuitry 714 may be configured to sense one or more signals via the electrodes 715, 719 and/or stimulate tissue via the electrodes 715, 719. As a result, the therapeutic circuitry 714 may pace, stimulate tissue, and/or sense a physiological condition at least partly in response to the one or more sensed signals. In some cases, the charging circuitry 710 and the therapeutic circuitry 714 may be located on distinct circuit boards or be manifested within distinct integrated circuits (ICs). In some cases, the charging circuitry 710 and the therapeutic circuitry 714, while shown as distinct elements, may be combined within a single IC or on a single circuit board.

While two electrodes 715, 719 are illustrated, it will be appreciated that in some instances the IMD 702 may include three, four or more distinct electrodes. Depending on the intended functionality of the IMD 702, as discussed above, the electrodes 715, 719 may be used for sensing and/or pacing the patient's heart. In some instances, for example, the IMD 702 may be a leadless cardiac pacemaker (LCP), an implantable monitoring device or an implantable sensor. In some cases, the electrodes 715, 719 may be used for communicating with other implanted devices and/or with external devices. In some cases, communication with other implanted devices may include conductive communication, but this is not required.

According to various embodiments, the controller 717 may be configured to monitor the operation of the IMD 702. For instance, the controller 717 may be configured to receive electrical signals from the charging circuitry 710. Based on the received signals, the controller 717 may detect the near-field energy received by the receiving coil 708 and generate a message regarding the near-field energy. For example, in some cases, the power transfer efficiency between the IMD 702 and a transmitter (e.g., transmitter 704) may depend on the relative orientation to one another and/or the distance between them. As such, when a transmit coil from the transmitter 704 is within a range of the receiving coil 708, a magnetic field may flow through the receiving coil 708 allowing the receiving coil 708 to receive the near-field energy. The charging circuitry 710 may use the near-field energy to charge the rechargeable power source 712 and send a signal to the controller 717 to indicate that the charging circuitry 710 is attempting to charge the rechargeable power source 712.

In some cases, the controller 717 may detect whether the signal meets a predetermined characteristic, condition or criteria. The predetermined characteristic, condition, or criteria may, for example, include a predetermined minimum energy capture rate by the receiving coil 708, a predetermined minimum voltage produced by the receiving coil 708, a predetermined minimum current produced by the receiving coil 708, and/or any other suitable characteristic or condition. In some situations, the rate at which the charging circuitry 710 is charging the rechargeable power source 712 may be less than the rate at which the rechargeable power source 712 is powering the IMD 702. As a result, the rechargeable power source 712 is still being depleted, albeit at a lower rate.

In some cases, the controller 717 may use the signal sent from the charging circuitry 710 (or other signal) to determine that the near-field energy from the transmitter and captured by the receiving coil 708 is not strong enough to meet the predetermined characteristic, condition or criteria. The controller 717 may then send a communication message (e.g., a signal) to the transmitter indicating that the rechargeable power source 712 is not charging sufficiently, and a user (e.g., the patient 700) may be presented with a notification. In some cases, the controller 717 may send a communication message to an external device, such as the patient's mobile phone or other device to alert the patient. In further embodiments, the message could be sent to a database over a network connection.

In some cases, the transmitter may include a user-interface with illuminating devises such as LED's, or audio devices, such as speakers or buzzers, to provide the notification. For example, a “not charging” message may be displayed using a red LED and a “charging” message may be displayed using a green LED. In this case, the patient 700 may observe that the red LED has turned on and may then realign the transmitter in response. In some cases, such a realignment may change the magnetic flux through the receiving coil 708 and increase the near-field energy received by the receiving coil 708. The charging circuitry 710 may then use the increased near-field energy to charge the rechargeable power source 712 and send a signal to the controller 717 to indicate that the charging circuitry 710 is once again, attempting to charge the rechargeable power source 712. In this case, the rate at which the charging circuitry 710 is charging the rechargeable power source 712 may be deemed acceptable. The controller 717 may then send a communication message to the transmitter indicating that the rechargeable power source 712 is charging. In this case, the “charging” message may be displayed to the patient by the green LED turning on.

As discussed above, in various embodiments, the controller 717 may be located on a pre-programmed VLSI chip, an ASIC, or on a programmable microprocessor. In some examples, regardless of whether the controller 717 is located on pre-programmed chip or a programmable microprocessor, the controller 717 may be programmed with logic where the controller 717 can send a message to alert the patient 700 about predetermined criteria or a high-priority condition requiring the patient's attention. For example, when the transmit coil from the transmitter 704 is within a range of the receiving coil 708, the magnetic field may flow through the receiving coil 708 allowing the receiving coil 708 to receive the near-field energy. The charging circuitry 710 may then use the near-field energy to charge the rechargeable power source 712. In this embodiment, the controller 717 may be programmed to detect whether the near-field energy received is great enough to charge the rechargeable power source 712. In another embodiment, the controller 717 may be programmed to detect whether the near-field energy received is great enough to charge the rechargeable power source 712 within a certain amount of time. For example, in some cases, the controller 717 may be programmed to detect whether the received near-field energy will fully charge the rechargeable power source 712 in 1 hour. In some cases, the controller 717 may be programmed to detect whether the received near-field energy will fully charge the rechargeable power source 712 in 8 hours. In some cases, the controller 717 may be programmed to detect whether the received near-field energy will fully charge the rechargeable power source 712 in 24 hours. In various embodiments, the charging of the rechargeable power source 712 or the rate at which the rechargeable power source 712 is charging may be predetermined characteristics, conditions or criteria, and the controller 717 may be programmed to alert the patient when there is a failure to charge the rechargeable power source 712 or a failure to meet the rate of charging or some other predetermined characteristic, condition or criteria.

Continuing with the current example, if the controller 717 detects that the rechargeable power source 712 is not charging or the rechargeable source 712 will not fully charge within a certain amount of time, the controller 717 may be programmed to send a communication message to the transmitter that turns on a red LED indicating that the rechargeable power source 712 is not charging adequately. Furthermore, if the controller 717 detects that the rechargeable power source 712 is charging or the rechargeable source 712 will fully charge within a certain amount of time, the controller 717 may be further programmed to send a communication message to the transmitter that turns on a green LED indicating that the rechargeable power source 712 is adequately charging. In some cases, the controller 717 may send a communication message to an external device, such as the patient's mobile phone. In some cases, when the transmitter receives a communication message that indicates the rechargeable power source 712 is not charging, the rechargeable source 712 will not fully charge within a certain amount of time, and/or the power received by the receiving coil 708 does not meet some other predetermined characteristic, condition or criteria, the transmitter may increase the transmit power to the transmit coil. This may include adjusting the frequency and/or amplitude of the signal provided to the transmit coil.

FIG. 9 provides an illustrative but non-limiting example of at least some of the components within an illustrative near-field energy transmitter 704. As shown, the illustrative near-field energy transmitter 704 may include a transmit coil 12, an output driver 14, a monitor 16, and a controller 18. In certain cases, the transmit coil may be configured to transmit near-field energy to an IMD (e.g., IMD 702) through inductive coupling. As discussed above, inductive coupling is the near-field wireless transmission of electrical energy between the transmitter 704 and the IMD 702. In some cases, the transmitter 704 may transfer power from the transmit coil 12 to a device inductor (e.g., receiving coil 708) by a magnetic field. In some cases, a signal generator (not shown) may generate an AC through the transmit coil 12 and create an oscillating magnetic field. The magnetic field may pass through the receiving coil 708 and induce an alternating EMF, which creates an AC in the IMD 702 to power a load (e.g., rechargeable power source 712).

In some cases, the transmit coil 12 may be fitted with a ferrite core. The high permeability, relative to the surrounding environment, may cause the magnetic field to be concentrated in the ferrite core. In some cases, the use of the ferrite core can concentrate the strength and increase the effect of magnetic fields produced by electric currents through the transmit coil 12. The magnetic field may also be confined and guided, using the ferrite core, and may improve coupling, thus, improving the transfer of power.

In various embodiments, the output driver 14 may be configured to drive the transmit coil 12 at a given frequency and amplitude. In certain embodiments, the output driver 14 may adjust the frequency and/or amplitude at which the near-field energy is transmitted. In some cases, the near-field energy received may depend on the inductive coupling between the transmit coil 12 and the receiving coil 708 and in some instances, the inductive coupling may depend on the frequency at which the transmit coil 12 is driven. As such, the near-field energy, and thus the power, transmitted by the transmit coil 12 may be larger when the transmit coil 12 is driven by the output driver 14 at one frequency over another frequency. In some cases, the closer the frequency at which the transmit coil 12 is driven is to a resonant frequency, the greater the power that is transmitted between the transmitter 704 and the IMD 702. At the resonant frequency, the transmit coil 12 and the receiving coil 708 may achieve resonant inductive coupling, where the transmitted power may reach a maximum. In some instances, when the transmit coil 12 and the receiving coil 708 achieve resonant inductive coupling, the transmitter 704 and the IMD 702 may interact with each other more strongly than they do with non-resonant objects, and power losses due to absorption in stray nearby objects may be reduced.

In some cases, a monitor 16 may be configured to detect a measure of the transmitted power from the transmit coil 12. The transmitted power may be dependent on the impedance matching between the transmitter (including the transmit coil) and the receiver of the IMD 702. The impedance of the receiver of the IMD 702 may include the input impedance of the receiving coil 708, the input impedance of the charging circuitry 710, and the impedance of the medium between the transmit coil and the receiving coil 708 (e.g. the patient's body). Since the impedance of the patient's body may change over time (e.g. with respiration, posture, activity level, etc.), the transmitted power may vary over time. To help increase the transmitted power, the transmitter may adjust, sometimes actively adjust, the frequency of the transmitted field to better match the impedance of the receiver of the IMD 702 (sometimes including the impedance of the patient's body therebetween).

In some cases, a controller 18 of the transmitter 704 may be operatively coupled to output driver 14 and monitor 16. The controller 18 may be configured to cause the output driver 14 to adjust the transmit frequency of the near-field energy across two or more transmit frequencies, identify the transmit power of the near-field energy at each of the two or more transmit frequencies using the monitor 16, select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic, condition or criteria, and set the transmit frequency of the output driver 14 to the selected transmit frequency.

In one example, the transmit coil 12 and the receiving coil 708 may achieve resonant inductive coupling at a resonant frequency. The resonant frequency may depend on, for example, the impedances of the transmit coil 12, the impedance of the receiving coil 708 and the impedance of the patient's body therebetween. As discussed above, the power transmitted by the transmit coil 12 may be larger as the transmit frequency becomes closer to the resonant frequency. The monitor 16 may detect the power transmitted at two or more different transmit frequencies, and the controller 18 may use this information to identify a frequency that will deliver sufficient power to the IMD 702. In some cases, the controller 18 may attempt to identify the resonance frequency. In some cases, the controller 18 may identify a suitable frequency for each of several detectable conditions, such an inhalation phase of the patient, an exhalation phase of the patient, the posture of the patient, the activity level of the patient, and/or any other detectable condition. Then, when a particular condition is detected, the controller 18 may transmit power at the corresponding identified frequency.

In some cases, the controller 18 may periodically monitor the operation of the transmitter 704 such that the transmitter 704 continues to update the suitable frequencies. In some cases, the monitoring may be initiated according to a triggering condition. For example, the controller 18 may detect a decrease in the power transmitted to the IMD 702 when the transmitter 704 is being run at a driven frequency. The controller 18 may then instruct the output driver 14 to adjust the frequencies to one or more other frequencies and instruct the monitor 16 to detect the transmitted powers at each of these frequency. The controller 18 may then identify the transmitted power values for each of these frequencies and store the transmitted power values. The controller 18 may then compare the transmitted power values and determine the frequency that delivers the maximum transmitted power to the IMD 702. The controller 18 may then set the output driver 14 to drive the transmit coil 12 at this frequency.

As discussed herein, power transmission may reach a maximum when the transmit coil 12 and the receiving coil 708 achieve resonant inductive coupling. Resonant inductive coupling may occur when the transmit coil 12 and the receiving coil 708 are configured to resonant at the same frequency and the transmit frequency equals the resonant frequency. In some cases, to configure the transmit coil 12 and the receiving coil 708 to resonant at the same or similar frequency, the impedance of the transmitter 704 may be changed to conform with the impedance of the IMD 702 (and in some cases, the patient's body therebetween).

In some instances, the impedance of the IMD 702 (and in some cases, the patient's body therebetween) may vary over time. For example, during the lifespan of the IMD 702, the internal impedance may change due to the aging of the circuitry of an IMD 702. In another example, the impedance may be affected by an implantation location of the IMD 702, and as a result, minor shifts or changes from the implantation location and/or orientation may change the internal impedance of the IMD 702. In addition, the location of the transmitter 704 relative to the IMD 702 may affect the impedance between the transmitter 704 and the IMD 702 (sometimes including the impedance of the patient's body therebetween), which may also affect the resonant frequency and the transmission of power. Also, changes in body posture, activity level, respiration and other characteristics of the patient may affect the impedance between the transmitter 704 and the IMD 702. To help compensate for these changes, the impedance of the transmitter may be changed over time. More specifically, the impedance of the output driver 14 and the transmit coil 12 may be adjusted to match the impedance of the IMD 702 (702 (sometimes including the impedance of the patient's body therebetween). This may help bring their resonance frequencies into alignment. Therefore, in some cases, the controller 18 may be configured to instruct the output driver 14 to adjust the impedance of the transmitter 704 such that the impedance of the output driver 14 and the transmit coil 12 may conform with the impedance of the IMD 702 and the impedance of the environment separating the transmitter 704 and the IMD 702 (e.g. the patient's body).

In some cases, the controller 18 may periodically monitor the operation of the transmitter 704 such that the transmitter 704 continues to transmit acceptable power. In some cases, the monitoring may be initiated according to a triggering condition. For example, the monitor 16 may detect a decrease in the power transmitted to the IMD 702. The controller 18 may then instruct the output driver 14 to adjust the impedance to change the resonance frequency of the transmitter 704 and drive the transmit coil 12 at the adjusted resonant frequency. The controller 18 may then instruct the monitor 16 to detect the transmitted power. This may be repeated from time to time.

In some cases, near-field energy transmitter 704 is operating to recharge a single IMD in which case output driver 14 and controller 18 are configured to optimally recharge the single IMD and monitor 16 indicates the status of the recharge of the single IMD. In other cases, the system may contain 2 or more IMDs, as indicated in FIG. 3, and near-field energy transmitter 704 operates to recharge the multiple IMDs. In this case, output driver 14 and controller 18 may be configured to optimally recharge the multiple IMDs and monitor 16 may indicate the status of the recharge of the multiple IMDs. In a system with multiple rechargeable IMDs, the transmitter 704 may simultaneously recharge both IMDs or preferentially recharge one or more IMDs based on the charge status of all the IMDs.

FIG. 10 provides another illustrative but non-limiting example of at least some of the components within the near-field energy transmitter 704. The configuration and operation of the near-field energy transmitter 704 and its elements may be similar to the configuration and operation of the near-field energy transmitter 704 and its elements described with respect to FIG. 9. In some cases, as seen in FIG. 10, the near-field energy transmitter 704 may also include a posture sensor 22. As discussed herein, in some cases, the location of the transmitter 704 relative to the IMD 702 may affect the impedance between the transmitter 704 and the IMD 702 which may also affect the transmission of power. Furthermore, the relative location of the IMD 702 within the patient 700 may depend on a posture of the patient 700. In some cases, the posture sensor 22 may be configured to detect the posture of the patient 700 and the controller 18 may be configured use the detection of the posture and respond to changes in the posture of the patient 700 to control the operation of the transmitter 704. For example, when the transmitter 704 is placed in the range to charge the IMD 702, the controller 18 may instruct the posture sensor 22 to detect the posture of the patient 700, which may be a first position. The controller 18 may then control the operation of the transmitter 704 to determine, select, and set the transmit frequency at which the output driver 14 drives the transmit coil 12 to achieve an acceptable power transmission to the IMD 701. The controller 18 may then associate this transmit frequency with the first position.

In some cases, the controller 18 may detect a decrease in the power transmitted to the IMD 702. In response, the controller 18 may instruct the posture sensor 22 to detect the posture of the patient 700, which may now be a second position different from the first position. The controller 18 may then control the operation of the transmitter 704 to determine, select, and set the transmit frequency at which the output driver 14 drives the transmit coil 12 to achieve an acceptable power transmission to the IMD 701. The controller 18 may then associate this transmit frequency with the second position.

In some cases, the controller 18 may once again detect a decrease in the power transmitted to the IMD 702. In response, the controller 18 may instruct the posture sensor 22 to detect the posture of the patient 700, which may now be a third position that is different from the first position and the second position. The controller 18 may then control the operation of the transmitter 704 to determine, select, and set the transmit frequency at which the output driver 14 drives the transmit coil 12 to achieve an acceptable power transmission to the IMD 701. The controller 18 may then associate this transmit frequency with the third position.

In some cases, at a later time, the controller 18 may monitor the posture of the patient via the posture sensor 22. When the posture of the patient 700 is detected to be the first position, the controller 18 may automatically switch to the transmit frequency that is associated with the first position. When the posture of the patient 700 is detected to be the second position, the controller 18 may automatically switch to the transmit frequency that is associated with the second position. When the posture of the patient 700 is detected to be the third position, the controller 18 may automatically switch to the transmit frequency that is associated with the third position.

A similar approach may be used in conjunction with a respiration sensor, an activity level sensor and/or any other suitable sensor. For example, with respect to a respiration sensor, the controller 18 may associate a first transmit frequency with an inhalation phase of the respiration cycle and a second transmit frequency with an exhalation phase of the respiration cycle. Then, when the respiration sensor detects an inhalation phase of the respiration cycle, the controller 18 may automatically switch to the first transmit frequency, and when the respiration sensor detects an exhalation phase of the respiration cycle, the controller 18 may automatically switch to the second transmit frequency.

FIG. 11 provides another illustrative but non-limiting example of at least some of the components within the near-field energy transmitter 704. The configuration and operation of the transmitter 704 and its elements may be similar to the configuration and operation of the transmitter 704 and its elements described with respect to FIG. 9. Furthermore, in some instances, the transmitter 704 may include the posture sensor 22 similar to the posture sensor 22 described with respect to FIG. 10. In some cases, as seen in FIG. 11, the transmitter 704 may include a communication block 26. The communication block 26 may be configured to communicate with devices such as sensors, other medical devices such as the IMD 702, and/or the like, that are located externally to the transmitter 704. Such devices may be located either external or internal to the patient's 700 body. Irrespective of the location, external devices (i.e. external to the transmitter 704 but not necessarily external to the patient's 700 body) can communicate with the transmitter 704 via communication block 26 to accomplish one or more desired functions. The communication block 26 may be configured to use one or more methods for communicating with the IMD 702. For example, the communication block 26 may communicate via radiofrequency (RF) signals, inductive coupling, optical signals, acoustic signals, conducted communication signals, and/or any other signals suitable for communication. In some cases, the transmitter 704 may communicate information, such as sensed electrical signals, data, instructions, messages, R-wave detection markers, etc., to the IMD 702 through the communication block 26. The transmitter 702 may additionally receive information such as signals, data, instructions and/or messages from the IMD 702 through the communication block 26, and the transmitter 704 may use the received signals, data, instructions and/or messages to perform various functions, such as charging the rechargeable power source 712, storing received data, and/or performing any other suitable function. In some cases, the communication block 26 may be used to enable communication between the transmitter 704 and the IMD 702 using the near-field energy. Near-Field communication is a wireless form of short range communication using near field magnetic flux for data transmission.

In certain instances, the communication block 26 may receive messages or information from the IMD 702 regarding the power transmitted from the near-field energy produced by the transmit coil 12. For example, when the patient 700 wants to charge the IMD 702, they may bring the transmitter 704 close to where the IMD 702 is located. In some cases, the communication block 26 may look for or poll for the nearby IMD 702 using the near-field energy. The IMD 702 may listen and respond by sending a signal back to the communication block 26 when the transmitter 704 is close enough. The communication block 26 may then decipher the signal and may send a signal to the controller 18 that the IMD 702 is within range and the controller 18 may begin the charging process. The controller 18 may then attempt to charge the rechargeable power source 712 by instructing the output driver 14 to drive the transmit coil 12 such that the near-field energy is transmitted at a first transmit frequency and/or amplitude. The communication block 26 may then receive a message from the IMD 702 regarding whether the transmitted power meets predetermined characteristic, condition or criteria. The communication block 26 may then send the message to the controller 18. In some instances, the controller 18 may perform a function or functions based on whether the transmitted power meets the predetermined characteristic, condition or criteria. For example, the strength of the transmitted power to the IMD 702 may not be enough to charge the rechargeable power source 712. As a result, the IMD 702 may send a message to the communication block 26 indicating that the transmitted power does not meet predetermined “charging” criteria. The communication block 26 of the transmitter 704 may then send the signal to the controller 18. Additionally or alternatively, in some cases, the communication block 26 may send a communication message to an external device, such as the patient's mobile phone. The controller 18 may then, for example, illuminate a red LED on a user-interface of the transmitter 704 to inform the patient 700 that the IMD 702 is not charging properly. In some cases, the patient may adjust the position of the transmitter 704 in an attempt to better align the transmitter 704 with the IMD 702. Alternatively, or in addition, the controller 18 may adjust the transmit frequency and/or transmit amplitude of the output driver 14 and thus the transmit coil 12 in an attempt to increase the transmitted power to the IMD 702. If the transmitted power is deemed sufficient, the IMD 702 may send a signal to the communication block 26 of the transmitter 704 indicating that the transmitted power meets the “charging” criteria. The communication block 26 may then send the signal to the controller 18. Additionally or alternatively, in some cases, the communication block 26 may send a communication message to the patient's mobile phone. In some cases, the controller may illuminate a green LED on the user-interface of the transmitter 704 to inform the patient 700 that the IMD 702 is now properly charging.

FIG. 12 provides another illustrative but non-limiting example of at least some of the components within the near-field energy transmitter 704. The configuration and operation of the transmitter 704 and its elements may be similar to the configuration and operation of the transmitter 704 and its elements described with respect to FIG. 9 and the transmitter 704 and its elements described with respect to FIG. 11. For example, when the patient 700 wants to charge the IMD 702, they may bring the transmitter 704 close to where the IMD 702 is located. In some cases, the communication block 26 may look for or poll for the nearby IMD 702 using the near-field energy. The IMD 702 may listen and respond by sending a signal back to the communication block 26 when the transmitter 704 is close enough. The communication block 26 may then decipher the signal and may send a signal to the controller 18 of the transmitter 704 that the IMD 702 is within range and the controller 18 may begin the charging process.

In some cases, the controller 18 may attempt to charge the rechargeable power source 712 by instructing the output driver 14 to drive the transmit coil 12 such that the near-field energy is transmitted at a transmit frequency and at a transmit amplitude. The communication block 26 may receive a message from the IMD 702 regarding whether the transmitted power meets one or more predetermined characteristics, conditions or criteria. The communication block 26 may forward the message to the controller 18. In some instances, the controller 18 may perform a function or functions based on whether the transmitted power meets the one or more predetermined characteristics, conditions or criteria.

In one example, the patient 700 may want to charge the IMD 702 within 1 hour. In such a case, a predetermined criteria may be whether the rate at which the rechargeable power source 712 is charging is great enough to fully charge the rechargeable power source 712 within 1 hour. In some cases, this rate may the rate needed to charge the rechargeable power source 712 from a completely discharged state to a fully charged state, or it may be the rate needed to charge the rechargeable power source 712 from the currently charged state (e.g. half charged) to a fully charged state (e.g. from half charged to fully charged). If the transmitted power to the IMD 702 is not sufficient to charge the rechargeable power source 712, the IMD 702 may send a message to the communication block 26 of the transmitter 704 indicating that the transmitted power (power received at the IMD 702) does not meet a “charging” criteria. The communication block 26 may forward the message to the controller 18. The controller 18 may illuminate a red LED on a user-interface of the transmitter 704 to inform the patient 700 that the IMD 702 is not charging. In some cases, the patient may adjust the position of the transmitter 704 in an attempt to better align the transmitter 704 with the IMD 702. Alternatively, or in addition, the controller 18 may adjust the transmit frequency and/or transmit amplitude, and instruct the output driver 14 to drive the transmit coil 12 at the adjusted transmit frequency and/or transmit amplitude. This time, the transmitted power to the IMD 702 may be sufficient to charge the rechargeable power source 712 but not within one hour. As a result, the IMD 702 may send a message to the communication block 26 indicating that the transmitted power still does not meet the “rate of charging” criteria. The communication block 26 may then send the message to the controller 18. In some cases, the controller 18 may illuminate a yellow LED on the user-interface of the transmitter 704 to show that the IMD 702 is charging, but not fast enough to be fully charged within 1 hour. In some cases, the patient may again adjust the position of the transmitter 704 in an attempt to better align the transmitter 704 with the IMD 702. Alternatively, or in addition, the controller 18 may adjust the transmit frequency and/or transmit amplitude, and instruct the output driver 14 to drive the transmit coil 12 at the adjusted transmit frequency and/or transmit amplitude. This time, the transmitted power to the IMD 702 may be sufficient to charge the rechargeable power source 712 within one hour. As a result, the IMD 702 may send a message to the communication block 26 indicating that the transmitted power meets the “rate of charging” criteria. The communication block 26 may then forward the message to the controller 18. In some cases, the controller 18 may illuminate a green LED on the user-interface of the transmitter 704 to show that the IMD 702 is charging at a rate that is fast enough to fully charge the rechargeable power source 712 within 1 hour. This is just one example.

FIG. 13A provides a schematic side-view and FIG. 13B provides a front-plan view of an illustration of a coil configuration 900 for a near-field transmitter (such as transmitter 704 of FIG. 9) containing multiple transmit coils 902a-902d. Each of the coils 902a-902d can be independently driven by output driver 906 to create near-field magnetic fields 904a-904d. Magnetic fields 904a-904d form composite magnetic field 910. Controller 908 may adjust the currents in coils 902a-902d thereby shifting the spatial peak (i.e. the transmit vector) of the composite magnetic field 910 to increase the power delivered to IMD 702. Adjusting the spatial peak of the composite magnetic field 910 may increase the power delivered to IMD 702 without the need for the patient to move transmitter 704.

FIG. 14A provides an illustrative but non-limiting example of a flexible substrate 30 that may house the transmit coil 12. The configuration and operation of the transmit coil 12 may be similar to the configuration and operation of the transmit coil 12 described with respect to FIGS. 9-12 when used in conjunction with the other elements included in the transmitter 704 described with respect to FIGS. 9-12.

In some cases, the substrate 30 may be formed of a flat woven fabric that defines a pocket 38. In some embodiments, the pocket 38 may include a flexible flap-like closure (not shown) which may be folded over the pocket 38 to contain the transmit coil 12 therein. According to various embodiments, the transmit coil 12 may be configured with low-resistive windings and an air-core front end. Furthermore, in some cases, the transmit coil 12 may be composed of a Litz wire and the spacing of the windings of the transmit coil 12 may be determined to potentially manage the thermal heating relating to the transmit coil 12.

In certain embodiments, the substrate 30 may be composed of one or more types of material that is commercially available and characterized by its flexibility and its ability to fit snuggly and/or comfortably to a piece of furniture (e.g., chair 48, from FIG. 14B) or a patient (e.g., patient 700, from FIG. 14C). Additionally, and in some cases, the substrate 30 may include target fiducials 32 sewn, printed, or painted on the surface of the substrate 30. In various embodiments, the target fiducials 32 may be used by the patient to assist the patient in aligning the transmit coil 12 with an IMD (e.g., IMD 702) within a patient (e.g., patient 700, from FIG. 14C).

In some cases, the substrate 30 may also be provided with supports for supporting the pocket 38 at various positions on the patient 700 (from FIG. 14C) or on a piece of furniture, such as the chair 48 (from FIG. 14B), a bed, a couch, etc. By way of example, the substrate 30 may include opposed elongated flexible fabric strap members 34a, 34b which are secured to the substrate 30 and extend normal to the opposed side edges 40a, 40b, respectively. The straps 34a, 34b may be formed of a suitable woven polyester fabric, for example. The distal ends of the straps 34a, 34b may be attached to connector members 42a, 42b that may take many forms, such as hooks, Velcro, screws, pins, clasps, buckles or another type of fastener that may secure connector members 42a, 42b to one another, respectively, after the position of the straps 34a, 34b are adjusted to properly secure the substrate 30 in a preferred position on the back of the chair 48, as shown in FIG. 14B, or on the patient's body 700, as shown in FIG. 14C.

In various embodiments, the substrate 30 may include a ferromagnetic shield (not shown). In certain configurations, the ferromagnetic shield may be located on a side of the transmit coil 12 that is opposite or faces away from the IMD 702. Such a ferromagnetic shield may help direct or focus the electromagnetic energy toward the IMD 702.

In some instances, the effectiveness of the ferromagnetic shield may depend on the material used, its thickness, the size of the shielded volume and the frequency of the fields of interest and the size, shape and orientation of apertures in a shield to an incident electromagnetic field. In some cases, the material used may include sheet metal, a metal screen, or metal foam. In some cases, the substrate 30 may be coated with metallic ink or similar material. The ink may include a carrier material loaded with a suitable metal, typically copper or nickel, in the form of very small particulates. It may be sprayed on the pocket 38 and, once dry, may produce a continuous conductive layer of metal. These are just examples.

In some cases, the ferromagnetic shield may be made of high magnetic permeability metal alloys, such as sheets of Permalloy and Mu-Metal, or with nanocrystalline grain structure ferromagnetic metal coatings. These materials may draw a stray magnetic field into themselves and provide a path for the magnetic field around the shielded volume. The effectiveness of this type of shielding may depend on the shield's permeability, which may drop off at low magnetic field strengths and at high field strengths where the shield becomes saturated. As a result, to achieve low residual fields, the ferromagnetic shield may include several enclosures, one inside the other, each of which successively may reduce the stray fields.

In various cases, active shielding may be used by creating a field with electromagnets to cancel the ambient field within the volume outside of the body. Solenoids and Helmholtz coils are types of coils that can be used for this purpose. Additionally, superconducting materials can expel magnetic fields via the Meissner effect.

In some cases, the flexible substrate 30 may include a user-interface 50 with illuminating devises such as LED's 52, or audio devices, such as speakers 54, to display or issue a human perceptible alert if the transmit coil 12 is deemed to be misaligned with the IMD 702. For example, in some cases, misalignment of the transmit coil 12 with the IMD 702 may cause the IMD 702 to not charge sufficiently when the near-field energy is applied and charging is expected. As a result, the LED 52 may be illuminated and/or the speakers 54 may release a “buzz” sound. The patient 700 may observe the illumination of the LED 52 and/or hear the “buzz” from the speakers 54 and realign the transmit coil 12 until the LED 52 is no longer illuminated and/or the speakers 54 stop releasing the “buzz” sound.

Referring now to FIG. 14B, the substrate 30 may also be configured as an elongated pad or pillow-like member with the transmit coil 12 disposed in the pocket 38 in the manner described above. In certain embodiments, there may be several transmit coils disposed in the pocket 38 to potentially increase the power transmission and decrease the charging time of the IMD 702. In some cases, a transmit coil may be selected from the transmit coils that offers the most efficient power transmission and potentially, the least amount of charging time for the IMD 702. Since the substrate 30 may be substantially flexible, the substrate 30 may be attached to a chair 48 and used as a lumbar pillow or as a neck or shoulder support while the transmit coil 12 applies the near-field energy, for example. In some cases, the substrate 30 may be attached to the chair 48 by wrapping the straps 34a, 34b around the chair 48 and attaching the connector members 42a, 42b to one another. Furthermore, to assist in aligning the transmit coil 12 with the IMD 702, target fiducials 32 may be used to show the patient where the patient 700 should position their torso relative to the transmit coil 12. As a result, the inductive coupling between the transmit coil 12 and a receiving coil of the IMD 702 may be enhanced and help increase the power transmission of the near-field energy.

Referring now to FIG. 14C, there is illustrated an illustrative position in which the substrate 30 may be worn by the patient 700. In some cases, because of the flexibility, the substrate 30 may conform to the contour of the body of the patient 700 to minimize discomfort and help the patient 700 don conventional outer garments which may not interfere with the substrate 30 or vice versa. In certain embodiments, a garment worn by the patient 700 may be the flexible substrate 30, and the transmit coil 12 may be located in or on the garment (e.g., in the pocket of a shirt). In some cases, the substrate 30 may be attached to the patient 700 by wrapping the straps 34a, 34b around the torso of the patient 700 and attaching the connector members 42a, 42b to one another. Furthermore, to assist in aligning the transmit coil 12 with the IMD 702, target fiducials 32 may be used to show the patient where the patient 700 should position the pocket 38 relative to a body part (e.g., the chest). As a result, the inductive coupling between the transmit coil 12 and the receiving coil of the IMD 702 may be enhanced and help increase the power transmission of the near-field energy.

FIG. 15A provides an illustrative but non-limiting example of another flexible substrate 40 that may house the transmit coil 12 and another transmit coil 42. The configuration and operation of the transmit coils 12, 42 may be similar to the configuration and operation of the transmit coil 12 described with respect to FIGS. 14A-14C. Furthermore, the operation and configuration of the flexible substrate 40 may be similar to the flexible substrate 30 as described with respect to FIGS. 14A-14C. In some cases, the user-interface 50 may be used to display or issue a human perceptible alert if the transmit coil 12 and/or the transmit coil 42 are deemed to be misaligned with the IMD 702.

Referring now to FIG. 15B, there is illustrated one position in which the substrate 40 of FIG. 15A may be worn by the patient 700. In some cases, because of the flexibility, the substrate 40 may wrap around the patient's 700 torso and conform to the contour of the body of the patient 700 to minimize discomfort and enable the patient 700 to don conventional outer garments which may not interfere with the substrate 40 or vice versa. In certain embodiments, the transmit coil 12 may be configured to be located on a front part 56 of the patient 700 and the transmit coil 42 may be configured to be located on a back part 58 of the patient 700. However, in other embodiments, one or more of the transmit coils 12, 42 may be configured to be located on another part of the patient 700, such as a side part 60. In some cases, the positioning of the transmit coil 12 relative to the transmit coil 42 may provide an increase in the focusing, steering, guiding, shaping, or confining of the near-field energy toward the IMD 702. In some cases, the transmit coil 42 may be used as an electromagnetic shield for the transmit coil 12 by creating a field to cancel, absorb, or minimize the ambient or stray fields or eddy-currents. In various embodiments, the transmit coil 12 and transmit coil 42 may communicate with one another, by way of feedback for example, to determine the alignment between the transmit coil 12 and the transmit 42. In addition, in some cases, the user-interface 50 may be configured to receive the feedback and use the LED 52 and/or speakers 54 to display or issue a human perceptible alert if the transmit coil 12 is deemed to be misaligned with the transmit coil 42.

It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments.

Claims

1. A near-field energy transmitter for charging an implantable medical device (IMD), the transmitter comprising: a transmit coil configured to transmit near-field energy to the IMD;an output driver for driving the transmit coil so that the transmit coil transmits the near-field energy at a transmit frequency, wherein the transmit frequency is adjustable;a monitor operatively coupled to the output driver for detecting a transmit power of the transmitted near-field energy;a controller operatively coupled to the output driver and the monitor, the controller configured to: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies;identify the transmit power of the near-field energy at each of the two or more transmit frequencies using the monitor;select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic, wherein the predetermined characteristic is that the transmit power is the maximum transmit power identified for the two or more transmit frequencies; andset the transmit frequency of the output driver to the selected transmit frequency.
2. The near-field energy transmitter of claim 1, wherein at least one of the transmit frequencies is a resonant frequency of the output driver and transmit coil, and the output driver comprises an adjustable impedance that is adjustable to produce the resonance frequency.
3. The near-field energy transmitter of claim 1, wherein the controller is configured to detect a decrease in the transmit power at the selected transmit frequency, and in response: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies;identify the transmit power of the near-field energy at each of the two or more transmit frequencies;select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic; andset the transmit frequency of the output driver to the selected transmit frequency.
4. The near-field energy transmitter of claim 1, wherein the controller is configured to repeat from time to time the following: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies;identify the transmit power of the near-field energy at each of the two or more transmit frequencies;select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic; andset the transmit frequency of the output driver to the selected transmit frequency.
5. The near-field energy transmitter of claim 1, further comprising a posture sensor for detecting a posture of a patient in which the IMD is implanted, and wherein the controller is configured to identify a transmit frequency for each of two or more postures by: using the posture sensor to detect when the patient is in one of the two or more postures, and when in the detected posture: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies;identify the transmit power of the near-field energy at each of the two or more transmit frequencies using the monitor;select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic; andassociate the detected posture with the selected transmit frequency.
6. The near-field energy transmitter of claim 5, wherein the controller is further configured to subsequently detect when the patient is in one of the two or more postures, and in response, set the transmit frequency of the output driver to the transmit frequency that is associated with the detected posture.
7. The near-field energy transmitter of claim 1, further comprising a communication block for communicating with the IMD, and wherein the communication block is configured to receive one or more messages from the IMD regarding the transmit power that is received by the IMD.
8. The near-field energy transmitter of claim 7, wherein: the output driver is configured to drive the transmit coil so that the transmit coil transmits the near-field energy at a transmit amplitude, wherein the transmit amplitude is adjustable; andthe controller is configured to adjust the transmit amplitude of the near-field energy so that the transmit power that is received by the IMD meets a predetermined criteria.
9. The near-field energy transmitter of claim 8, wherein the one or more messages received from the IMD indicate whether the transmit power that is received by the IMD meets the predetermined criteria.
10. The near-field energy transmitter of claim 8, wherein the one or more messages received from the IMD indicate whether the transmit power that is received by the IMD does not meet the predetermined criteria.
11. The near-field energy transmitter of claim 1, further comprising a flexible substrate configured to conform to a patient and house the transmitter coil.
12. The near-field energy transmitter of claim 11, wherein the flexible substrate comprises a strap for securing the flexible substrate in place, and wherein the flexible substrate has target fiducials to indicate a torso position of the patient relative to the transmit coil.
13. The near-field energy transmitter of claim 11, further comprising a ferromagnetic shield along a side of the transmit coil that faces away from the IMD during use.
14. The near-field energy transmitter of claim 11, wherein the flexible substrate is configured to be worn by the patient.
15. The near-field energy transmitter of claim 14, further comprising a second transmit coil housed by the flexible substrate, wherein the transmit coil is configured to be located on a front of the patient and the second transmit coil is configured to be located on a side or back of the patient.
16. The near-field energy transmitter of claim 11, wherein the controller is further configured to issue a human perceptible alert if the transmit coil is deemed to be misaligned with the 1 MB.
17. A near-field energy transmitter for charging an implantable medical device (1 MB), the transmitter comprising: a transmit coil configured to transmit near-field energy to the IMD;an output driver for driving the transmit coil so that the transmit coil transmits the near-field energy at a transmit frequency and a transmit amplitude, wherein at least one of the transmit frequency and transmit amplitude is adjustable;a communication block for communicating with the IMD, wherein the communication block is configured to receive one or more messages from the IMD regarding the transmit power that is received by the IMD; anda controller operatively coupled to the output driver and the communication block, the controller configured to adjust one or more of the transmit frequency and transmit amplitude of the near-field energy so that the transmit power that is received by the IMD meets a predetermined criteria.
18. The near-field energy transmitter of claim 17, wherein the one or more messages received from the IMD indicate: whether the transmit power that is received by the IMD meets the predetermined criteria; and/orwhether the transmit power that is received by the IMD does not meet the predetermined criteria.
19. A near-field energy transmitter for charging an implantable medical device (IMD), the transmitter comprising: a transmit coil configured to transmit near-field energy to the IMD;an output driver for driving the transmit coil so that the transmit coil transmits the near-field energy at a transmit frequency, wherein the transmit frequency is adjustable;a monitor operatively coupled to the output driver for detecting a transmit power of the transmitted near-field energy;a controller operatively coupled to the output driver and the monitor, the controller configured to: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies;identify the transmit power of the near-field energy at each of the two or more transmit frequencies using the monitor;select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic; andset the transmit frequency of the output driver to the selected transmit frequency;wherein the controller is configured to detect a decrease in the transmit power at the selected transmit frequency, and in response: cause the output driver to adjust the transmit frequency of the near-field energy across two or more transmit frequencies;identify the transmit power of the near-field energy at each of the two or more transmit frequencies;select the transmit frequency of the two or more transmit frequencies that results in a transmit power that has a predetermined characteristic; andset the transmit frequency of the output driver to the selected transmit frequency.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/424,918 filed on Nov. 21, 2016, the disclosure of which is incorporated herein by reference.

US Referenced Citations (1150)

Number	Name	Date	Kind
3835864	Rasor et al.	Sep 1974	A
3943936	Rasor et al.	Mar 1976	A
4142530	Wittkampf	Mar 1979	A
4151513	Menken et al.	Apr 1979	A
4157720	Greatbatch	Jun 1979	A
RE30366	Rasor et al.	Aug 1980	E
4243045	Maas	Jan 1981	A
4250884	Hartlaub et al.	Feb 1981	A
4256115	Bilitch	Mar 1981	A
4263919	Levin	Apr 1981	A
4310000	Lindemans	Jan 1982	A
4312354	Walters	Jan 1982	A
4323081	Wiebusch	Apr 1982	A
4357946	Dutcher et al.	Nov 1982	A
4365639	Goldreyer	Dec 1982	A
4440173	Hudziak et al.	Apr 1984	A
4476868	Thompson	Oct 1984	A
4522208	Buffet	Jun 1985	A
4537200	Widrow	Aug 1985	A
4556063	Thompson et al.	Dec 1985	A
4562841	Brockway et al.	Jan 1986	A
4593702	Kepski et al.	Jun 1986	A
4593955	Leiber	Jun 1986	A
4630611	King	Dec 1986	A
4635639	Hakala et al.	Jan 1987	A
4674508	DeCote	Jun 1987	A
4712554	Garson	Dec 1987	A
4729376	DeCote	Mar 1988	A
4754753	King	Jul 1988	A
4759366	Callaghan	Jul 1988	A
4776338	Lekholm et al.	Oct 1988	A
4787389	Tarjan	Nov 1988	A
4793353	Borkan	Dec 1988	A
4819662	Heil et al.	Apr 1989	A
4858610	Callaghan et al.	Aug 1989	A
4886064	Strandberg	Dec 1989	A
4887609	Cole, Jr.	Dec 1989	A
4928688	Mower	May 1990	A
4967746	Vandegriff	Nov 1990	A
4987897	Funke	Jan 1991	A
4989602	Sholder et al.	Feb 1991	A
5012806	De Bellis	May 1991	A
5036849	Hauck et al.	Aug 1991	A
5040534	Mann et al.	Aug 1991	A
5058581	Silvian	Oct 1991	A
5078134	Heilman et al.	Jan 1992	A
5109845	Yuuchi et al.	May 1992	A
5113859	Funke	May 1992	A
5113869	Nappholz et al.	May 1992	A
5117824	Keimel et al.	Jun 1992	A
5127401	Grevious et al.	Jul 1992	A
5133353	Hauser	Jul 1992	A
5144950	Stoop et al.	Sep 1992	A
5170784	Ramon et al.	Dec 1992	A
5179945	Van Hofwegen et al.	Jan 1993	A
5193539	Schulman et al.	Mar 1993	A
5193540	Schulman et al.	Mar 1993	A
5241961	Henry	Sep 1993	A
5243977	Trabucco et al.	Sep 1993	A
5259387	dePinto	Nov 1993	A
5269326	Verrier	Dec 1993	A
5284136	Hauck et al.	Feb 1994	A
5300107	Stokes et al.	Apr 1994	A
5301677	Hsung	Apr 1994	A
5305760	McKown et al.	Apr 1994	A
5312439	Loeb	May 1994	A
5313953	Yomtov et al.	May 1994	A
5314459	Swanson et al.	May 1994	A
5318597	Hauck et al.	Jun 1994	A
5324316	Schulman et al.	Jun 1994	A
5331966	Bennett et al.	Jul 1994	A
5334222	Salo et al.	Aug 1994	A
5342408	Decoriolis et al.	Aug 1994	A
5370667	Alt	Dec 1994	A
5372606	Lang et al.	Dec 1994	A
5376106	Stahmann et al.	Dec 1994	A
5383915	Adams	Jan 1995	A
5388578	Yomtov et al.	Feb 1995	A
5404877	Nolan et al.	Apr 1995	A
5405367	Schulman et al.	Apr 1995	A
5411031	Yomtov	May 1995	A
5411525	Swanson et al.	May 1995	A
5411535	Fujii et al.	May 1995	A
5456691	Snell	Oct 1995	A
5458622	Alt	Oct 1995	A
5466246	Silvian	Nov 1995	A
5468254	Hahn et al.	Nov 1995	A
5472453	Alt	Dec 1995	A
5522866	Fernald	Jun 1996	A
5540727	Tockman et al.	Jul 1996	A
5545186	Olson et al.	Aug 1996	A
5545202	Dahl et al.	Aug 1996	A
5571146	Jones et al.	Nov 1996	A
5591214	Lu	Jan 1997	A
5620466	Haefner et al.	Apr 1997	A
5634938	Swanson et al.	Jun 1997	A
5649968	Alt et al.	Jul 1997	A
5662688	Haefner et al.	Sep 1997	A
5674259	Gray	Oct 1997	A
5683426	Greenhut et al.	Nov 1997	A
5683432	Goedeke et al.	Nov 1997	A
5706823	Wodlinger	Jan 1998	A
5709215	Perttu et al.	Jan 1998	A
5720770	Nappholz et al.	Feb 1998	A
5728154	Crossett et al.	Mar 1998	A
5741314	Daly et al.	Apr 1998	A
5741315	Lee et al.	Apr 1998	A
5752976	Duffin et al.	May 1998	A
5752977	Grevious et al.	May 1998	A
5755736	Gillberg et al.	May 1998	A
5759199	Snell et al.	Jun 1998	A
5774501	Halpern et al.	Jun 1998	A
5792195	Carlson et al.	Aug 1998	A
5792202	Rueter	Aug 1998	A
5792203	Schroeppel	Aug 1998	A
5792205	Alt et al.	Aug 1998	A
5792208	Gray	Aug 1998	A
5814089	Stokes et al.	Sep 1998	A
5827216	Igo et al.	Oct 1998	A
5836985	Goyal et al.	Nov 1998	A
5836987	Baumann et al.	Nov 1998	A
5842977	Lesho et al.	Dec 1998	A
5855593	Olson et al.	Jan 1999	A
5871625	Leddy et al.	Feb 1999	A
5873894	Vandegriff et al.	Feb 1999	A
5891184	Lee et al.	Apr 1999	A
5897586	Molina	Apr 1999	A
5899876	Flower	May 1999	A
5899928	Sholder et al.	May 1999	A
5919214	Ciciarelli et al.	Jul 1999	A
5928804	Leddy et al.	Jul 1999	A
5935078	Feierbach	Aug 1999	A
5941906	Barreras et al.	Aug 1999	A
5944744	Paul et al.	Aug 1999	A
5954757	Gray	Sep 1999	A
5978713	Prutchi et al.	Nov 1999	A
5981095	Leddy et al.	Nov 1999	A
5991660	Goyal	Nov 1999	A
5991661	Park et al.	Nov 1999	A
5999848	Gord et al.	Dec 1999	A
5999857	Weijand et al.	Dec 1999	A
6016445	Baura	Jan 2000	A
6026320	Carlson et al.	Feb 2000	A
6029085	Olson et al.	Feb 2000	A
6041250	dePinto	Mar 2000	A
6044298	Salo et al.	Mar 2000	A
6044300	Gray	Mar 2000	A
6055454	Heemels	Apr 2000	A
6073050	Griffith	Jun 2000	A
6076016	Feierbach	Jun 2000	A
6077236	Cunningham	Jun 2000	A
6080187	Alt et al.	Jun 2000	A
6083248	Thompson	Jul 2000	A
6106551	Crossett et al.	Aug 2000	A
6115636	Ryan	Sep 2000	A
6128526	Stadler et al.	Oct 2000	A
6141581	Olson et al.	Oct 2000	A
6141588	Cox et al.	Oct 2000	A
6141592	Pauly	Oct 2000	A
6144879	Gray	Nov 2000	A
6162195	Igo et al.	Dec 2000	A
6164284	Schulman et al.	Dec 2000	A
6167310	Grevious	Dec 2000	A
6201993	Kruse et al.	Mar 2001	B1
6207313	Leddy et al.	Mar 2001	B1
6208894	Schulman et al.	Mar 2001	B1
6211799	Post et al.	Apr 2001	B1
6221011	Bardy	Apr 2001	B1
6240316	Richmond et al.	May 2001	B1
6240317	Villaseca et al.	May 2001	B1
6256534	Dahl	Jul 2001	B1
6259947	Olson et al.	Jul 2001	B1
6266558	Gozani et al.	Jul 2001	B1
6266567	Ishikawa et al.	Jul 2001	B1
6270457	Bardy	Aug 2001	B1
6272377	Sweeney et al.	Aug 2001	B1
6273856	Sun et al.	Aug 2001	B1
6277072	Bardy	Aug 2001	B1
6280380	Bardy	Aug 2001	B1
6285907	Kramer et al.	Sep 2001	B1
6292698	Duffin et al.	Sep 2001	B1
6295473	Rosar	Sep 2001	B1
6297943	Carson	Oct 2001	B1
6298271	Weijand	Oct 2001	B1
6307751	Bodony et al.	Oct 2001	B1
6312378	Bardy	Nov 2001	B1
6315721	Schulman et al.	Nov 2001	B2
6322676	Leddy et al.	Nov 2001	B1
6336903	Bardy	Jan 2002	B1
6345202	Richmond et al.	Feb 2002	B2
6351667	Godie	Feb 2002	B1
6351669	Hartley et al.	Feb 2002	B1
6353759	Hartley et al.	Mar 2002	B1
6355166	Amarasinghe et al.	Mar 2002	B1
6358203	Bardy	Mar 2002	B2
6361780	Ley et al.	Mar 2002	B1
6368284	Bardy	Apr 2002	B1
6371922	Baumann et al.	Apr 2002	B1
6398728	Bardy	Jun 2002	B1
6400982	Sweeney et al.	Jun 2002	B2
6400990	Silvian	Jun 2002	B1
6408208	Sun	Jun 2002	B1
6409674	Brockway et al.	Jun 2002	B1
6411848	Kramer et al.	Jun 2002	B2
6424865	Ding	Jul 2002	B1
6434429	Kraus et al.	Aug 2002	B1
6438410	Hsu et al.	Aug 2002	B2
6438417	Rockwell et al.	Aug 2002	B1
6438421	Stahmann et al.	Aug 2002	B1
6440066	Bardy	Aug 2002	B1
6441747	Khair et al.	Aug 2002	B1
6442426	Kroll	Aug 2002	B1
6442432	Lee	Aug 2002	B2
6443891	Grevious	Sep 2002	B1
6445953	Bulkes et al.	Sep 2002	B1
6453200	Koslar	Sep 2002	B1
6459929	Hopper et al.	Oct 2002	B1
6470215	Kraus et al.	Oct 2002	B1
6471645	Warkentin et al.	Oct 2002	B1
6479176	Leddy et al.	Nov 2002	B2
6480745	Nelson et al.	Nov 2002	B2
6487443	Olson et al.	Nov 2002	B2
6490487	Kraus et al.	Dec 2002	B1
6498951	Larson et al.	Dec 2002	B1
6507755	Gozani et al.	Jan 2003	B1
6507759	Prutchi et al.	Jan 2003	B1
6512940	Brabec et al.	Jan 2003	B1
6522915	Ceballos et al.	Feb 2003	B1
6526311	Begemann	Feb 2003	B2
6539253	Thompson et al.	Mar 2003	B2
6542775	Ding et al.	Apr 2003	B2
6553258	Stahmann et al.	Apr 2003	B2
6561975	Pool et al.	May 2003	B1
6564807	Schulman et al.	May 2003	B1
6574506	Kramer et al.	Jun 2003	B2
6584351	Ekwall	Jun 2003	B1
6584352	Combs et al.	Jun 2003	B2
6597948	Rockwell et al.	Jul 2003	B1
6597951	Kramer et al.	Jul 2003	B2
6622046	Fraley et al.	Sep 2003	B2
6628985	Sweeney et al.	Sep 2003	B2
6647292	Bardy et al.	Nov 2003	B1
6666844	Igo et al.	Dec 2003	B1
6689117	Sweeney et al.	Feb 2004	B2
6690959	Thompson	Feb 2004	B2
6694189	Begemann	Feb 2004	B2
6704602	Berg et al.	Mar 2004	B2
6718212	Parry et al.	Apr 2004	B2
6721597	Bardy et al.	Apr 2004	B1
6738670	Almendinger et al.	May 2004	B1
6746797	Benson et al.	Jun 2004	B2
6749566	Russ	Jun 2004	B2
6758810	Lebel et al.	Jul 2004	B2
6763269	Cox	Jul 2004	B2
6766200	Cox	Jul 2004	B2
6778860	Ostroff et al.	Aug 2004	B2
6788971	Sloman et al.	Sep 2004	B1
6788974	Bardy et al.	Sep 2004	B2
6804558	Haller et al.	Oct 2004	B2
6807442	Myklebust et al.	Oct 2004	B1
6847844	Sun et al.	Jan 2005	B2
6871095	Stahmann et al.	Mar 2005	B2
6878112	Linberg et al.	Apr 2005	B2
6885889	Chinchoy	Apr 2005	B2
6890670	Leddy et al.	May 2005	B2
6892094	Ousdigian et al.	May 2005	B2
6897788	Khair et al.	May 2005	B2
6904315	Panken et al.	Jun 2005	B2
6922592	Thompson et al.	Jul 2005	B2
6931282	Esler	Aug 2005	B2
6934585	Schloss et al.	Aug 2005	B1
6957107	Rogers et al.	Oct 2005	B2
6978176	Lattouf	Dec 2005	B2
6985773	Von Arx et al.	Jan 2006	B2
6990375	Kloss et al.	Jan 2006	B2
7001366	Ballard	Feb 2006	B2
7003350	Denker et al.	Feb 2006	B2
7006864	Echt et al.	Feb 2006	B2
7013178	Reinke et al.	Mar 2006	B2
7027871	Burnes et al.	Apr 2006	B2
7050849	Echt et al.	May 2006	B2
7060031	Webb et al.	Jun 2006	B2
7063693	Guenst	Jun 2006	B2
7082336	Ransbury et al.	Jul 2006	B2
7085606	Flach et al.	Aug 2006	B2
7092758	Sun et al.	Aug 2006	B2
7110824	Amundson et al.	Sep 2006	B2
7120504	Osypka	Oct 2006	B2
7130681	Gebhardt et al.	Oct 2006	B2
7139613	Reinke et al.	Nov 2006	B2
7142912	Wagner et al.	Nov 2006	B2
7146225	Guenst et al.	Dec 2006	B2
7146226	Lau et al.	Dec 2006	B2
7149581	Goedeke	Dec 2006	B2
7149588	Lau et al.	Dec 2006	B2
7158839	Lau	Jan 2007	B2
7162307	Patrias	Jan 2007	B2
7164952	Lau et al.	Jan 2007	B2
7177700	Cox	Feb 2007	B1
7181505	Haller et al.	Feb 2007	B2
7184830	Echt et al.	Feb 2007	B2
7186214	Ness	Mar 2007	B2
7191015	Lamson et al.	Mar 2007	B2
7200437	Nabutovsky et al.	Apr 2007	B1
7200439	Zdeblick et al.	Apr 2007	B2
7206423	Feng et al.	Apr 2007	B1
7209785	Kim et al.	Apr 2007	B2
7209790	Thompson et al.	Apr 2007	B2
7211884	Davis et al.	May 2007	B1
7212871	Morgan	May 2007	B1
7225032	Schmeling et al.	May 2007	B2
7226440	Gelfand et al.	Jun 2007	B2
7228183	Sun et al.	Jun 2007	B2
7236821	Cates et al.	Jun 2007	B2
7236829	Farazi et al.	Jun 2007	B1
7254448	Almendinger et al.	Aug 2007	B2
7260436	Kilgore et al.	Aug 2007	B2
7270669	Sra	Sep 2007	B1
7272448	Morgan et al.	Sep 2007	B1
7277755	Falkenberg et al.	Oct 2007	B1
7280872	Mosesov et al.	Oct 2007	B1
7288096	Chin	Oct 2007	B2
7289847	Gill et al.	Oct 2007	B1
7289852	Helfinstine et al.	Oct 2007	B2
7289853	Campbell et al.	Oct 2007	B1
7289855	Nghiem et al.	Oct 2007	B2
7302294	Kamath et al.	Nov 2007	B2
7305266	Kroll	Dec 2007	B1
7310556	Bulkes	Dec 2007	B2
7319905	Morgan et al.	Jan 2008	B1
7333853	Mazar et al.	Feb 2008	B2
7336994	Hettrick et al.	Feb 2008	B2
7347819	Lebel et al.	Mar 2008	B2
7366572	Heruth et al.	Apr 2008	B2
7373207	Lattouf	May 2008	B2
7384403	Sherman	Jun 2008	B2
7386342	Falkenberg et al.	Jun 2008	B1
7392090	Sweeney et al.	Jun 2008	B2
7406105	DelMain et al.	Jul 2008	B2
7406349	Seeberger et al.	Jul 2008	B2
7410497	Hastings et al.	Aug 2008	B2
7425200	Brockway et al.	Sep 2008	B2
7433739	Salys et al.	Oct 2008	B1
7496409	Greenhut et al.	Feb 2009	B2
7496410	Heil	Feb 2009	B2
7502652	Gaunt et al.	Mar 2009	B2
7512448	Malick et al.	Mar 2009	B2
7515969	Tockman et al.	Apr 2009	B2
7526342	Chin et al.	Apr 2009	B2
7529589	Williams et al.	May 2009	B2
7532933	Hastings et al.	May 2009	B2
7536222	Bardy et al.	May 2009	B2
7536224	Ritscher et al.	May 2009	B2
7539541	Quiles et al.	May 2009	B2
7544197	Kelsch et al.	Jun 2009	B2
7558631	Cowan et al.	Jul 2009	B2
7565195	Kroll et al.	Jul 2009	B1
7584002	Burnes et al.	Sep 2009	B2
7590455	Heruth et al.	Sep 2009	B2
7606621	Brisken et al.	Oct 2009	B2
7610088	Chinchoy	Oct 2009	B2
7610092	Cowan et al.	Oct 2009	B2
7610099	Almendinger et al.	Oct 2009	B2
7610104	Kaplan et al.	Oct 2009	B2
7616991	Mann et al.	Nov 2009	B2
7617001	Penner et al.	Nov 2009	B2
7617007	Williams et al.	Nov 2009	B2
7630767	Poore et al.	Dec 2009	B1
7634313	Kroll et al.	Dec 2009	B1
7637867	Zdeblick	Dec 2009	B2
7640060	Zdeblick	Dec 2009	B2
7647109	Hastings et al.	Jan 2010	B2
7650186	Hastings et al.	Jan 2010	B2
7657311	Bardy et al.	Feb 2010	B2
7668596	Von Arx et al.	Feb 2010	B2
7682316	Anderson et al.	Mar 2010	B2
7691047	Ferrari	Apr 2010	B2
7702392	Echt et al.	Apr 2010	B2
7713194	Zdeblick	May 2010	B2
7713195	Zdeblick	May 2010	B2
7729783	Michels et al.	Jun 2010	B2
7734333	Ghanem et al.	Jun 2010	B2
7734343	Ransbury et al.	Jun 2010	B2
7738958	Zdeblick et al.	Jun 2010	B2
7738964	Von Arx et al.	Jun 2010	B2
7742812	Ghanem et al.	Jun 2010	B2
7742816	Masoud et al.	Jun 2010	B2
7742822	Masoud et al.	Jun 2010	B2
7743151	Vallapureddy et al.	Jun 2010	B2
7747335	Williams	Jun 2010	B2
7751881	Cowan et al.	Jul 2010	B2
7758521	Morris et al.	Jul 2010	B2
7761150	Ghanem et al.	Jul 2010	B2
7761164	Verhoef et al.	Jul 2010	B2
7765001	Echt et al.	Jul 2010	B2
7769452	Ghanem et al.	Aug 2010	B2
7783362	Whitehurst et al.	Aug 2010	B2
7792588	Harding	Sep 2010	B2
7797059	Bornzin et al.	Sep 2010	B1
7801596	Fischell et al.	Sep 2010	B2
7809438	Echt et al.	Oct 2010	B2
7840281	Kveen et al.	Nov 2010	B2
7844331	Li et al.	Nov 2010	B2
7844348	Swoyer et al.	Nov 2010	B2
7846088	Ness	Dec 2010	B2
7848815	Brisken et al.	Dec 2010	B2
7848823	Drasler et al.	Dec 2010	B2
7860455	Fukumoto et al.	Dec 2010	B2
7871433	Lattouf	Jan 2011	B2
7877136	Moffitt et al.	Jan 2011	B1
7877142	Moaddeb et al.	Jan 2011	B2
7881786	Jackson	Feb 2011	B2
7881798	Miesel et al.	Feb 2011	B2
7881810	Chitre et al.	Feb 2011	B1
7890173	Brisken et al.	Feb 2011	B2
7890181	Denzene et al.	Feb 2011	B2
7890192	Kelsch et al.	Feb 2011	B1
7894885	Bartal et al.	Feb 2011	B2
7894894	Stadler et al.	Feb 2011	B2
7894907	Cowan et al.	Feb 2011	B2
7894910	Cowan et al.	Feb 2011	B2
7894915	Chitre et al.	Feb 2011	B1
7899537	Kroll et al.	Mar 2011	B1
7899541	Cowan et al.	Mar 2011	B2
7899542	Cowan et al.	Mar 2011	B2
7899554	Williams et al.	Mar 2011	B2
7901360	Yang et al.	Mar 2011	B1
7904170	Harding	Mar 2011	B2
7907993	Ghanem et al.	Mar 2011	B2
7920928	Yang et al.	Apr 2011	B1
7925343	Min et al.	Apr 2011	B1
7930022	Zhang et al.	Apr 2011	B2
7930040	Kelsch et al.	Apr 2011	B1
7937135	Ghanem et al.	May 2011	B2
7937148	Jacobson	May 2011	B2
7937161	Hastings et al.	May 2011	B2
7941214	Kleckner et al.	May 2011	B2
7945333	Jacobson	May 2011	B2
7946997	Hübinette	May 2011	B2
7949404	Hill	May 2011	B2
7949405	Feher	May 2011	B2
7953486	Daum et al.	May 2011	B2
7953493	Fowler et al.	May 2011	B2
7962202	Bhunia	Jun 2011	B2
7974702	Fain et al.	Jul 2011	B1
7979136	Young et al.	Jul 2011	B2
7983753	Severin	Jul 2011	B2
7991467	Markowitz et al.	Aug 2011	B2
7991471	Ghanem et al.	Aug 2011	B2
7996087	Cowan et al.	Aug 2011	B2
8000791	Sunagawa et al.	Aug 2011	B2
8000807	Morris et al.	Aug 2011	B2
8001975	DiSilvestro et al.	Aug 2011	B2
8002700	Ferek-Petric et al.	Aug 2011	B2
8010209	Jacobson	Aug 2011	B2
8019419	Panescu et al.	Sep 2011	B1
8019434	Dulles et al.	Sep 2011	B2
8027727	Freeberg	Sep 2011	B2
8027729	Sunagawa et al.	Sep 2011	B2
8032219	Neumann et al.	Oct 2011	B2
8036743	Savage et al.	Oct 2011	B2
8046079	Bange et al.	Oct 2011	B2
8046080	Von Arx et al.	Oct 2011	B2
8050297	Delmain et al.	Nov 2011	B2
8050759	Stegemann et al.	Nov 2011	B2
8050774	Kveen et al.	Nov 2011	B2
8055345	Li et al.	Nov 2011	B2
8055350	Roberts	Nov 2011	B2
8060212	Rios et al.	Nov 2011	B1
8065018	Haubrich et al.	Nov 2011	B2
8073542	Doerr	Dec 2011	B2
8078278	Penner	Dec 2011	B2
8078283	Cowan et al.	Dec 2011	B2
8095123	Gray	Jan 2012	B2
8102789	Rosar et al.	Jan 2012	B2
8103359	Reddy	Jan 2012	B2
8103361	Moser	Jan 2012	B2
8112148	Giftakis et al.	Feb 2012	B2
8114021	Robertson et al.	Feb 2012	B2
8121680	Falkenberg et al.	Feb 2012	B2
8123684	Zdeblick	Feb 2012	B2
8126545	Flach et al.	Feb 2012	B2
8131334	Lu et al.	Mar 2012	B2
8140161	Willerton et al.	Mar 2012	B2
8140168	Olson et al.	Mar 2012	B2
8150521	Crowley et al.	Apr 2012	B2
8160672	Kim et al.	Apr 2012	B2
8160702	Mann et al.	Apr 2012	B2
8160704	Freeberg	Apr 2012	B2
8165694	Carbanaru et al.	Apr 2012	B2
8175715	Cox	May 2012	B1
8180451	Hickman et al.	May 2012	B2
8185213	Kveen et al.	May 2012	B2
8187161	Li et al.	May 2012	B2
8195293	Limousin et al.	Jun 2012	B2
8204595	Pianca et al.	Jun 2012	B2
8204605	Hastings et al.	Jun 2012	B2
8209014	Doerr	Jun 2012	B2
8214043	Matos	Jul 2012	B2
8224244	Kim et al.	Jul 2012	B2
8229556	Li	Jul 2012	B2
8233985	Bulkes et al.	Jul 2012	B2
8265748	Liu et al.	Sep 2012	B2
8265757	Mass et al.	Sep 2012	B2
8262578	Bharmi et al.	Oct 2012	B1
8280521	Haubrich et al.	Oct 2012	B2
8285387	Utsi et al.	Oct 2012	B2
8290598	Boon et al.	Oct 2012	B2
8290600	Hastings et al.	Oct 2012	B2
8295939	Jacobson	Oct 2012	B2
8301254	Mosesov et al.	Oct 2012	B2
8315701	Cowan et al.	Nov 2012	B2
8315708	Berthelsdorf et al.	Nov 2012	B2
8321021	Kisker et al.	Nov 2012	B2
8321036	Brockway et al.	Nov 2012	B2
8332036	Hastings et al.	Dec 2012	B2
8335563	Stessman	Dec 2012	B2
8335568	Heruth et al.	Dec 2012	B2
8340750	Prakash et al.	Dec 2012	B2
8340780	Hastings et al.	Dec 2012	B2
8352025	Jacobson	Jan 2013	B2
8352028	Wenger	Jan 2013	B2
8352038	Mao et al.	Jan 2013	B2
8359098	Lund et al.	Jan 2013	B2
8364261	Stubbs et al.	Jan 2013	B2
8364276	Willis	Jan 2013	B2
8369959	Meskens	Feb 2013	B2
8369962	Abrahamson	Feb 2013	B2
8380320	Spital	Feb 2013	B2
8386051	Rys	Feb 2013	B2
8391981	Mosesov	Mar 2013	B2
8391990	Smith et al.	Mar 2013	B2
8406874	Liu et al.	Mar 2013	B2
8406879	Shuros et al.	Mar 2013	B2
8406886	Gaunt et al.	Mar 2013	B2
8412352	Griswold et al.	Apr 2013	B2
8417340	Goossen	Apr 2013	B2
8417341	Freeberg	Apr 2013	B2
8423149	Hennig	Apr 2013	B2
8428722	Verhoef et al.	Apr 2013	B2
8433402	Ruben et al.	Apr 2013	B2
8433409	Johnson et al.	Apr 2013	B2
8433420	Bange et al.	Apr 2013	B2
8447412	Dal Molin et al.	May 2013	B2
8452413	Young et al.	May 2013	B2
8457740	Osche	Jun 2013	B2
8457742	Jacobson	Jun 2013	B2
8457744	Janzig et al.	Jun 2013	B2
8457761	Wariar	Jun 2013	B2
8478407	Demmer et al.	Jul 2013	B2
8478408	Hastings et al.	Jul 2013	B2
8478431	Griswold et al.	Jul 2013	B2
8494632	Sun et al.	Jul 2013	B2
8504156	Bonner et al.	Aug 2013	B2
8509910	Sowder et al.	Aug 2013	B2
8515559	Roberts et al.	Aug 2013	B2
8525340	Eckhardt et al.	Sep 2013	B2
8527068	Ostroff	Sep 2013	B2
8532790	Griswold	Sep 2013	B2
8538526	Stahmann et al.	Sep 2013	B2
8541131	Lund et al.	Sep 2013	B2
8543205	Ostroff	Sep 2013	B2
8547248	Zdeblick et al.	Oct 2013	B2
8548605	Ollivier	Oct 2013	B2
8554322	Olson et al.	Oct 2013	B2
8554333	Wu et al.	Oct 2013	B2
8565882	Matos	Oct 2013	B2
8565897	Regnier et al.	Oct 2013	B2
8571678	Wang	Oct 2013	B2
8577327	Makdissi et al.	Nov 2013	B2
8588926	Moore et al.	Nov 2013	B2
8612002	Faltys et al.	Dec 2013	B2
8615310	Khairkhahan et al.	Dec 2013	B2
8626280	Allavatam et al.	Jan 2014	B2
8626294	Sheldon et al.	Jan 2014	B2
8630717	Olson et al.	Jan 2014	B2
8634908	Cowan	Jan 2014	B2
8634912	Bornzin et al.	Jan 2014	B2
8634919	Hou et al.	Jan 2014	B1
8639335	Peichel et al.	Jan 2014	B2
8644934	Hastings et al.	Feb 2014	B2
8649859	Smith et al.	Feb 2014	B2
8670842	Bornzin et al.	Mar 2014	B1
8676319	Knoll	Mar 2014	B2
8676335	Katoozi et al.	Mar 2014	B2
8700173	Edlund	Apr 2014	B2
8700181	Bornzin et al.	Apr 2014	B2
8705599	dal Molin et al.	Apr 2014	B2
8718766	Wahlberg	May 2014	B2
8718773	Willis et al.	May 2014	B2
8725260	Shuros et al.	May 2014	B2
8738133	Shuros et al.	May 2014	B2
8738147	Hastings et al.	May 2014	B2
8744555	Allavatam et al.	Jun 2014	B2
8744572	Greenhut et al.	Jun 2014	B1
8747314	Stahmann et al.	Jun 2014	B2
8755884	Demmer et al.	Jun 2014	B2
8758365	Bonner et al.	Jun 2014	B2
8768483	Schmitt et al.	Jul 2014	B2
8774572	Hamamoto	Jul 2014	B2
8781605	Bornzin et al.	Jul 2014	B2
8788035	Jacobson	Jul 2014	B2
8788053	Jacobson	Jul 2014	B2
8798740	Samade et al.	Aug 2014	B2
8798745	Jacobson	Aug 2014	B2
8798762	Fain et al.	Aug 2014	B2
8798770	Reddy	Aug 2014	B2
8805505	Roberts	Aug 2014	B1
8805528	Corndorf	Aug 2014	B2
8812109	Blomqvist et al.	Aug 2014	B2
8818504	Bodner et al.	Aug 2014	B2
8827913	Havel et al.	Sep 2014	B2
8831747	Min et al.	Sep 2014	B1
8855789	Jacobson	Oct 2014	B2
8868186	Kroll	Oct 2014	B2
8886339	Faltys et al.	Nov 2014	B2
8903473	Rogers et al.	Dec 2014	B2
8903500	Smith et al.	Dec 2014	B2
8903513	Ollivier	Dec 2014	B2
8909336	Navarro-Paredes et al.	Dec 2014	B2
8914131	Bornzin et al.	Dec 2014	B2
8923795	Makdissi et al.	Dec 2014	B2
8923963	Bonner et al.	Dec 2014	B2
8938300	Rosero	Jan 2015	B2
8942806	Sheldon et al.	Jan 2015	B2
8958892	Khairkhahan et al.	Feb 2015	B2
8977358	Ewert et al.	Mar 2015	B2
8989873	Locsin	Mar 2015	B2
8996109	Karst et al.	Mar 2015	B2
9002467	Smith et al.	Apr 2015	B2
9008776	Cowan et al.	Apr 2015	B2
9008777	Dianaty et al.	Apr 2015	B2
9014818	Deterre et al.	Apr 2015	B2
9017341	Bornzin et al.	Apr 2015	B2
9020611	Khairkhahan et al.	Apr 2015	B2
9037262	Regnier et al.	May 2015	B2
9042984	Demmer et al.	May 2015	B2
9072911	Hastings et al.	Jul 2015	B2
9072913	Jacobson	Jul 2015	B2
9155882	Grubac et al.	Oct 2015	B2
9168372	Fain	Oct 2015	B2
9168380	Greenhut et al.	Oct 2015	B1
9168383	Jacobson et al.	Oct 2015	B2
9180285	Moore et al.	Nov 2015	B2
9192774	Jacobson	Nov 2015	B2
9205225	Khairkhahan et al.	Dec 2015	B2
9216285	Boling et al.	Dec 2015	B1
9216293	Berthiaume et al.	Dec 2015	B2
9216297	Kast et al.	Dec 2015	B2
9216298	Jacobson	Dec 2015	B2
9227077	Jacobson	Jan 2016	B2
9238145	Wenzel et al.	Jan 2016	B2
9242102	Khairkhahan et al.	Jan 2016	B2
9242113	Smith et al.	Jan 2016	B2
9248300	Rys et al.	Feb 2016	B2
9265436	Min et al.	Feb 2016	B2
9265962	Dianaty et al.	Feb 2016	B2
9272155	Ostroff	Mar 2016	B2
9278218	Karst et al.	Mar 2016	B2
9278229	Reinke et al.	Mar 2016	B1
9283381	Grubac et al.	Mar 2016	B2
9283382	Berthiaume et al.	Mar 2016	B2
9289612	Sambelashvili et al.	Mar 2016	B1
9302115	Molin et al.	Apr 2016	B2
9333364	Echt et al.	May 2016	B2
9333365	Zhao	May 2016	B2
9358387	Suwito et al.	Jun 2016	B2
9358400	Jacobson	Jun 2016	B2
9364675	Deterre et al.	Jun 2016	B2
9370663	Moulder	Jun 2016	B2
9375580	Bonner et al.	Jun 2016	B2
9375581	Baru et al.	Jun 2016	B2
9381365	Kibler et al.	Jul 2016	B2
9393405	Hastings et al.	Jul 2016	B2
9393424	Demmer et al.	Jul 2016	B2
9393436	Doerr	Jul 2016	B2
9399139	Demmer et al.	Jul 2016	B2
9399140	Cho et al.	Jul 2016	B2
9409033	Jacobson	Aug 2016	B2
9427594	Bornzin et al.	Aug 2016	B1
9431694	Li et al.	Aug 2016	B2
9433368	Stahmann et al.	Sep 2016	B2
9433780	Régnier et al.	Sep 2016	B2
9457193	Klimovitch et al.	Oct 2016	B2
9492668	Sheldon et al.	Nov 2016	B2
9492669	Demmer et al.	Nov 2016	B2
9492674	Schmidt et al.	Nov 2016	B2
9492677	Greenhut et al.	Nov 2016	B2
9511233	Sambelashvili	Dec 2016	B2
9511236	Varady et al.	Dec 2016	B2
9511237	Deterre et al.	Dec 2016	B2
9522276	Shen et al.	Dec 2016	B2
9522280	Fishler et al.	Dec 2016	B2
9526522	Wood et al.	Dec 2016	B2
9526891	Eggen et al.	Dec 2016	B2
9526909	Stahmann et al.	Dec 2016	B2
9533163	Klimovitch et al.	Jan 2017	B2
9561382	Persson et al.	Feb 2017	B2
9566012	Greenhut et al.	Feb 2017	B2
9636511	Carney et al.	May 2017	B2
9669223	Auricchio et al.	Jun 2017	B2
9687654	Sheldon et al.	Jun 2017	B2
9687655	Pertijs et al.	Jun 2017	B2
9687659	Von Arx et al.	Jun 2017	B2
9694186	Carney et al.	Jul 2017	B2
9782594	Stahmann et al.	Oct 2017	B2
9782601	Ludwig	Oct 2017	B2
9789317	Greenhut et al.	Oct 2017	B2
9789319	Sambelashvili	Oct 2017	B2
9808617	Ostroff et al.	Nov 2017	B2
9808628	Sheldon et al.	Nov 2017	B2
9808631	Maile et al.	Nov 2017	B2
9808632	Reinke et al.	Nov 2017	B2
9808633	Bonner et al.	Nov 2017	B2
9808637	Sharma et al.	Nov 2017	B2
20020032470	Linberg	Mar 2002	A1
20020035376	Bardy et al.	Mar 2002	A1
20020035377	Bardy et al.	Mar 2002	A1
20020035378	Bardy et al.	Mar 2002	A1
20020035380	Rissmann et al.	Mar 2002	A1
20020035381	Bardy et al.	Mar 2002	A1
20020042629	Bardy et al.	Apr 2002	A1
20020042630	Bardy et al.	Apr 2002	A1
20020042634	Bardy et al.	Apr 2002	A1
20020049475	Bardy et al.	Apr 2002	A1
20020052636	Bardy et al.	May 2002	A1
20020068958	Bardy et al.	Jun 2002	A1
20020072773	Bardy et al.	Jun 2002	A1
20020082665	Haller et al.	Jun 2002	A1
20020091414	Bardy et al.	Jul 2002	A1
20020095196	Linberg	Jul 2002	A1
20020099423	Berg et al.	Jul 2002	A1
20020103510	Bardy et al.	Aug 2002	A1
20020107545	Rissmann et al.	Aug 2002	A1
20020107546	Ostroff et al.	Aug 2002	A1
20020107547	Erlinger et al.	Aug 2002	A1
20020107548	Bardy et al.	Aug 2002	A1
20020107549	Bardy et al.	Aug 2002	A1
20020107559	Sanders et al.	Aug 2002	A1
20020120299	Ostroff et al.	Aug 2002	A1
20020173830	Starkweather et al.	Nov 2002	A1
20020193846	Pool et al.	Dec 2002	A1
20030009203	Lebel et al.	Jan 2003	A1
20030028082	Thompson	Feb 2003	A1
20030040779	Engmark et al.	Feb 2003	A1
20030041866	Linberg et al.	Mar 2003	A1
20030045805	Sheldon et al.	Mar 2003	A1
20030088278	Bardy et al.	May 2003	A1
20030097153	Bardy et al.	May 2003	A1
20030105497	Zhu et al.	Jun 2003	A1
20030114908	Flach	Jun 2003	A1
20030144701	Mehra et al.	Jul 2003	A1
20030187460	Chin et al.	Oct 2003	A1
20030187461	Chin	Oct 2003	A1
20040024435	Leckrone et al.	Feb 2004	A1
20040068302	Rodgers et al.	Apr 2004	A1
20040087938	Leckrone et al.	May 2004	A1
20040088035	Guenst et al.	May 2004	A1
20040102830	Williams	May 2004	A1
20040127959	Amundson et al.	Jul 2004	A1
20040133242	Chapman et al.	Jul 2004	A1
20040147969	Mann et al.	Jul 2004	A1
20040147973	Hauser	Jul 2004	A1
20040167558	Igo et al.	Aug 2004	A1
20040167587	Thompson	Aug 2004	A1
20040172071	Bardy et al.	Sep 2004	A1
20040172077	Chinchoy	Sep 2004	A1
20040172104	Berg et al.	Sep 2004	A1
20040176817	Wahlstrand et al.	Sep 2004	A1
20040176818	Wahlstrand et al.	Sep 2004	A1
20040176830	Fang	Sep 2004	A1
20040186529	Bardy et al.	Sep 2004	A1
20040204673	Flaherty	Oct 2004	A1
20040210292	Bardy et al.	Oct 2004	A1
20040210293	Bardy et al.	Oct 2004	A1
20040210294	Bardy et al.	Oct 2004	A1
20040215308	Bardy et al.	Oct 2004	A1
20040220624	Ritscher et al.	Nov 2004	A1
20040220626	Wagner	Nov 2004	A1
20040220639	Mulligan et al.	Nov 2004	A1
20040249431	Ransbury et al.	Dec 2004	A1
20040260348	Bakken et al.	Dec 2004	A1
20040267303	Guenst	Dec 2004	A1
20050061320	Lee et al.	Mar 2005	A1
20050070962	Echt et al.	Mar 2005	A1
20050102003	Grabek et al.	May 2005	A1
20050149138	Min et al.	Jul 2005	A1
20050165466	Morris et al.	Jul 2005	A1
20050182465	Ness	Aug 2005	A1
20050203410	Jenkins	Sep 2005	A1
20050283208	Von Arx et al.	Dec 2005	A1
20050288743	Ahn et al.	Dec 2005	A1
20060042830	Maghribi et al.	Mar 2006	A1
20060052829	Sun et al.	Mar 2006	A1
20060052830	Spinelli et al.	Mar 2006	A1
20060064135	Brockway	Mar 2006	A1
20060064149	Belacazar et al.	Mar 2006	A1
20060085039	Hastings et al.	Apr 2006	A1
20060085041	Hastings et al.	Apr 2006	A1
20060085042	Hastings et al.	Apr 2006	A1
20060095078	Tronnes	May 2006	A1
20060106442	Richardson et al.	May 2006	A1
20060116746	Chin	Jun 2006	A1
20060135999	Bodner et al.	Jun 2006	A1
20060136004	Cowan et al.	Jun 2006	A1
20060161061	Echt et al.	Jul 2006	A1
20060200002	Guenst	Sep 2006	A1
20060206151	Lu	Sep 2006	A1
20060212079	Routh et al.	Sep 2006	A1
20060241701	Markowitz et al.	Oct 2006	A1
20060241705	Neumann et al.	Oct 2006	A1
20060247672	Vidlund et al.	Nov 2006	A1
20060259088	Pastore et al.	Nov 2006	A1
20060265018	Smith et al.	Nov 2006	A1
20070004979	Wojciechowicz et al.	Jan 2007	A1
20070016098	Kim et al.	Jan 2007	A1
20070027508	Cowan	Feb 2007	A1
20070078490	Cowan et al.	Apr 2007	A1
20070088394	Jacobson	Apr 2007	A1
20070088396	Jacobson	Apr 2007	A1
20070088397	Jacobson	Apr 2007	A1
20070088398	Jacobson	Apr 2007	A1
20070088405	Jacobson	Apr 2007	A1
20070135882	Drasler et al.	Jun 2007	A1
20070135883	Drasler et al.	Jun 2007	A1
20070150037	Hastings et al.	Jun 2007	A1
20070150038	Hastings et al.	Jun 2007	A1
20070156190	Cinbis	Jul 2007	A1
20070219525	Gelfand et al.	Sep 2007	A1
20070219590	Hastings et al.	Sep 2007	A1
20070225545	Ferrari	Sep 2007	A1
20070233206	Frikart et al.	Oct 2007	A1
20070239244	Morgan et al.	Oct 2007	A1
20070255376	Michels et al.	Nov 2007	A1
20070276444	Gelbart et al.	Nov 2007	A1
20070293900	Sheldon et al.	Dec 2007	A1
20070293904	Gelbart et al.	Dec 2007	A1
20080004663	Jorgenson	Jan 2008	A1
20080021505	Hastings et al.	Jan 2008	A1
20080021519	De Geest et al.	Jan 2008	A1
20080021532	Kveen et al.	Jan 2008	A1
20080065183	Whitehurst et al.	Mar 2008	A1
20080065185	Worley	Mar 2008	A1
20080071318	Brooke et al.	Mar 2008	A1
20080071328	Haubrich et al.	Mar 2008	A1
20080109054	Hastings et al.	May 2008	A1
20080119911	Rosero	May 2008	A1
20080130670	Kim et al.	Jun 2008	A1
20080154139	Shuros et al.	Jun 2008	A1
20080154322	Jackson et al.	Jun 2008	A1
20080228234	Stancer	Sep 2008	A1
20080234771	Chinchoy et al.	Sep 2008	A1
20080243217	Wildon	Oct 2008	A1
20080262573	Seeberger et al.	Oct 2008	A1
20080269814	Rosero	Oct 2008	A1
20080269825	Chinchoy et al.	Oct 2008	A1
20080275518	Ghanem et al.	Nov 2008	A1
20080275519	Ghanem et al.	Nov 2008	A1
20080288039	Reddy	Nov 2008	A1
20080294208	Willis et al.	Nov 2008	A1
20080294210	Rosero	Nov 2008	A1
20080306359	Zdeblick et al.	Dec 2008	A1
20090018599	Hastings et al.	Jan 2009	A1
20090024180	Kisker et al.	Jan 2009	A1
20090036941	Corbucci	Feb 2009	A1
20090048646	Katoozi et al.	Feb 2009	A1
20090062895	Stahmann et al.	Mar 2009	A1
20090082827	Kveen et al.	Mar 2009	A1
20090082828	Ostroff	Mar 2009	A1
20090088813	Brockway et al.	Apr 2009	A1
20090131907	Chin et al.	May 2009	A1
20090135886	Robertson et al.	May 2009	A1
20090143835	Pastore et al.	Jun 2009	A1
20090171408	Solem	Jul 2009	A1
20090171414	Kelly et al.	Jul 2009	A1
20090204163	Shuros et al.	Aug 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090210024	M	Aug 2009	A1
20090216292	Pless et al.	Aug 2009	A1
20090234407	Hastings et al.	Sep 2009	A1
20090234411	Sambelashvili et al.	Sep 2009	A1
20090266573	Engmark et al.	Oct 2009	A1
20090275998	Burnes et al.	Nov 2009	A1
20090275999	Burnes et al.	Nov 2009	A1
20090299447	Jensen et al.	Dec 2009	A1
20100013668	Kantervik	Jan 2010	A1
20100016911	Willis et al.	Jan 2010	A1
20100023085	Wu et al.	Jan 2010	A1
20100030061	Canfield et al.	Feb 2010	A1
20100030327	Chatel	Feb 2010	A1
20100042108	Hibino	Feb 2010	A1
20100056871	Govari et al.	Mar 2010	A1
20100063375	Kassab et al.	Mar 2010	A1
20100063562	Cowan et al.	Mar 2010	A1
20100094367	Sen	Apr 2010	A1
20100114209	Krause et al.	May 2010	A1
20100114214	Morelli et al.	May 2010	A1
20100125281	Jacobson et al.	May 2010	A1
20100168761	Kassab et al.	Jul 2010	A1
20100168819	Freeberg	Jul 2010	A1
20100198288	Ostroff	Aug 2010	A1
20100198304	Wang	Aug 2010	A1
20100217367	Belson	Aug 2010	A1
20100228308	Cowan et al.	Sep 2010	A1
20100234906	Koh	Sep 2010	A1
20100234924	Willis	Sep 2010	A1
20100241185	Mahapatra et al.	Sep 2010	A1
20100249729	Morris et al.	Sep 2010	A1
20100286744	Echt et al.	Nov 2010	A1
20100312309	Harding	Dec 2010	A1
20110022113	Zdeblick et al.	Jan 2011	A1
20110066211	Von Arx et al.	Mar 2011	A1
20110071586	Jacobson	Mar 2011	A1
20110077708	Ostroff	Mar 2011	A1
20110112600	Cowan et al.	May 2011	A1
20110118588	Komblau et al.	May 2011	A1
20110118810	Cowan et al.	May 2011	A1
20110137187	Yang et al.	Jun 2011	A1
20110144720	Cowan et al.	Jun 2011	A1
20110152970	Jollota et al.	Jun 2011	A1
20110160558	Rassatt et al.	Jun 2011	A1
20110160565	Stubbs et al.	Jun 2011	A1
20110160801	Markowitz et al.	Jun 2011	A1
20110160806	Lyden et al.	Jun 2011	A1
20110166620	Cowan et al.	Jul 2011	A1
20110166621	Cowan et al.	Jul 2011	A1
20110184491	Kivi	Jul 2011	A1
20110190835	Brockway et al.	Aug 2011	A1
20110208260	Jacobson	Aug 2011	A1
20110218587	Jacobson	Sep 2011	A1
20110230734	Fain et al.	Sep 2011	A1
20110237967	Moore et al.	Sep 2011	A1
20110245890	Brisben et al.	Oct 2011	A1
20110251660	Griswold	Oct 2011	A1
20110251662	Griswold et al.	Oct 2011	A1
20110270099	Ruben et al.	Nov 2011	A1
20110270339	Murray, III et al.	Nov 2011	A1
20110270340	Pellegrini et al.	Nov 2011	A1
20110276102	Cohen	Nov 2011	A1
20110282423	Jacobson	Nov 2011	A1
20120004527	Thompson et al.	Jan 2012	A1
20120029323	Zhao	Feb 2012	A1
20120041508	Rousso et al.	Feb 2012	A1
20120059433	Cowan et al.	Mar 2012	A1
20120059436	Fontaine et al.	Mar 2012	A1
20120065500	Rogers et al.	Mar 2012	A1
20120078322	Dal Molin et al.	Mar 2012	A1
20120089198	Ostroff	Apr 2012	A1
20120093245	Makdissi et al.	Apr 2012	A1
20120095521	Hintz	Apr 2012	A1
20120095539	Khairkhahan et al.	Apr 2012	A1
20120101540	O'Brien et al.	Apr 2012	A1
20120101553	Reddy	Apr 2012	A1
20120109148	Bonner et al.	May 2012	A1
20120109149	Bonner et al.	May 2012	A1
20120109236	Jacobson et al.	May 2012	A1
20120109259	Bond et al.	May 2012	A1
20120116489	Khairkhahan et al.	May 2012	A1
20120150251	Giftakis et al.	Jun 2012	A1
20120158111	Khairkhahan et al.	Jun 2012	A1
20120165827	Khairkhahan et al.	Jun 2012	A1
20120172690	Anderson et al.	Jul 2012	A1
20120172891	Lee	Jul 2012	A1
20120172892	Grubac et al.	Jul 2012	A1
20120172942	Berg	Jul 2012	A1
20120197350	Roberts et al.	Aug 2012	A1
20120197373	Khairkhahan et al.	Aug 2012	A1
20120215285	Tahmasian et al.	Aug 2012	A1
20120232565	Kveen et al.	Sep 2012	A1
20120277600	Greenhut	Nov 2012	A1
20120277606	Ellingson et al.	Nov 2012	A1
20120283795	Stancer et al.	Nov 2012	A1
20120283807	Deterre et al.	Nov 2012	A1
20120290025	Keimel	Nov 2012	A1
20120296381	Matos	Nov 2012	A1
20120303082	Dong et al.	Nov 2012	A1
20120316613	Keefe et al.	Dec 2012	A1
20130012151	Hankins	Jan 2013	A1
20130023975	Locsin	Jan 2013	A1
20130035748	Bonner et al.	Feb 2013	A1
20130041422	Jacobson	Feb 2013	A1
20130053908	Smith et al.	Feb 2013	A1
20130053915	Holmstrom et al.	Feb 2013	A1
20130053921	Bonner et al.	Feb 2013	A1
20130060298	Splett et al.	Mar 2013	A1
20130066169	Rys et al.	Mar 2013	A1
20130072770	Rao et al.	Mar 2013	A1
20130079798	Tran et al.	Mar 2013	A1
20130079861	Reinert et al.	Mar 2013	A1
20130085350	Schugt et al.	Apr 2013	A1
20130085403	Gunderson et al.	Apr 2013	A1
20130085550	Polefko et al.	Apr 2013	A1
20130096649	Martin et al.	Apr 2013	A1
20130103047	Steingisser et al.	Apr 2013	A1
20130103109	Jacobson	Apr 2013	A1
20130110008	Bourget et al.	May 2013	A1
20130110127	Bornzin et al.	May 2013	A1
20130110192	Tran et al.	May 2013	A1
20130110219	Bornzin et al.	May 2013	A1
20130116529	Min et al.	May 2013	A1
20130116738	Samade et al.	May 2013	A1
20130116740	Bornzin et al.	May 2013	A1
20130116741	Bornzin et al.	May 2013	A1
20130123872	Bornzin et al.	May 2013	A1
20130123875	Varady et al.	May 2013	A1
20130131591	Berthiaume et al.	May 2013	A1
20130131693	Berthiaume et al.	May 2013	A1
20130138006	Bornzin et al.	May 2013	A1
20130150695	Biela et al.	Jun 2013	A1
20130150911	Perschbacher et al.	Jun 2013	A1
20130150912	Perschbacher et al.	Jun 2013	A1
20130184776	Shuros et al.	Jul 2013	A1
20130196703	Masoud et al.	Aug 2013	A1
20130197609	Moore et al.	Aug 2013	A1
20130231710	Jacobson	Sep 2013	A1
20130238072	Deterre et al.	Sep 2013	A1
20130238073	Makdissi et al.	Sep 2013	A1
20130253342	Griswold et al.	Sep 2013	A1
20130253343	Waldhauser et al.	Sep 2013	A1
20130253344	Griswold et al.	Sep 2013	A1
20130253345	Griswold et al.	Sep 2013	A1
20130253346	Griswold et al.	Sep 2013	A1
20130253347	Griswold et al.	Sep 2013	A1
20130261497	Pertijs et al.	Oct 2013	A1
20130265144	Banna et al.	Oct 2013	A1
20130268042	Hastings et al.	Oct 2013	A1
20130274828	Willis	Oct 2013	A1
20130274847	Ostroff	Oct 2013	A1
20130282070	Cowan et al.	Oct 2013	A1
20130282073	Cowan et al.	Oct 2013	A1
20130296727	Sullivan et al.	Nov 2013	A1
20130303872	Taff et al.	Nov 2013	A1
20130324825	Ostroff et al.	Dec 2013	A1
20130325081	Karst et al.	Dec 2013	A1
20130345770	Dianaty et al.	Dec 2013	A1
20140012344	Hastings et al.	Jan 2014	A1
20140018876	Ostroff	Jan 2014	A1
20140018877	Demmer et al.	Jan 2014	A1
20140031836	Ollivier	Jan 2014	A1
20140039570	Carroll et al.	Feb 2014	A1
20140039591	Drasler et al.	Feb 2014	A1
20140043146	Makdissi et al.	Feb 2014	A1
20140046395	Regnier et al.	Feb 2014	A1
20140046420	Moore et al.	Feb 2014	A1
20140058240	Mothilal et al.	Feb 2014	A1
20140058494	Ostroff et al.	Feb 2014	A1
20140074114	Khairkhahan et al.	Mar 2014	A1
20140074186	Faltys et al.	Mar 2014	A1
20140094891	Pare et al.	Apr 2014	A1
20140100627	Min	Apr 2014	A1
20140107723	Hou et al.	Apr 2014	A1
20140121719	Bonner et al.	May 2014	A1
20140121720	Bonner et al.	May 2014	A1
20140121722	Sheldon et al.	May 2014	A1
20140128935	Kumar et al.	May 2014	A1
20140135865	Hastings et al.	May 2014	A1
20140142648	Smith et al.	May 2014	A1
20140148675	Nordstrom et al.	May 2014	A1
20140148815	Wenzel et al.	May 2014	A1
20140155950	Hastings et al.	Jun 2014	A1
20140169162	Romano et al.	Jun 2014	A1
20140172060	Bornzin et al.	Jun 2014	A1
20140180306	Grubac et al.	Jun 2014	A1
20140180366	Edlund	Jun 2014	A1
20140207149	Hastings et al.	Jul 2014	A1
20140207210	Willis et al.	Jul 2014	A1
20140214104	Greenhut et al.	Jul 2014	A1
20140222098	Baru et al.	Aug 2014	A1
20140222109	Moulder	Aug 2014	A1
20140228913	Molin et al.	Aug 2014	A1
20140236172	Hastings et al.	Aug 2014	A1
20140243848	Auricchio et al.	Aug 2014	A1
20140255298	Cole et al.	Sep 2014	A1
20140257324	Fain	Sep 2014	A1
20140257422	Herken	Sep 2014	A1
20140257444	Cole et al.	Sep 2014	A1
20140276929	Foster et al.	Sep 2014	A1
20140309706	Jacobson	Oct 2014	A1
20140379041	Foster	Dec 2014	A1
20150025612	Haasl et al.	Jan 2015	A1
20150039041	Smith et al.	Feb 2015	A1
20150051609	Schmidt et al.	Feb 2015	A1
20150051610	Schmidt et al.	Feb 2015	A1
20150051611	Schmidt et al.	Feb 2015	A1
20150051612	Schmidt et al.	Feb 2015	A1
20150051613	Schmidt et al.	Feb 2015	A1
20150051614	Schmidt et al.	Feb 2015	A1
20150051615	Schmidt et al.	Feb 2015	A1
20150051616	Haasl et al.	Feb 2015	A1
20150051682	Schmidt et al.	Feb 2015	A1
20150057520	Foster et al.	Feb 2015	A1
20150057558	Stahmann et al.	Feb 2015	A1
20150057721	Stahmann et al.	Feb 2015	A1
20150088155	Stahmann et al.	Mar 2015	A1
20150105836	Bonner et al.	Apr 2015	A1
20150157861	Aghassian	Jun 2015	A1
20150173655	Demmer et al.	Jun 2015	A1
20150190638	Smith et al.	Jul 2015	A1
20150196756	Stahmann et al.	Jul 2015	A1
20150196757	Stahmann et al.	Jul 2015	A1
20150196758	Stahmann et al.	Jul 2015	A1
20150196769	Stahmann et al.	Jul 2015	A1
20150217119	Nikolski et al.	Aug 2015	A1
20150221898	Chi et al.	Aug 2015	A1
20150224315	Stahmann	Aug 2015	A1
20150224320	Stahmann	Aug 2015	A1
20150224323	Chen et al.	Aug 2015	A1
20150258345	Smith et al.	Sep 2015	A1
20150290468	Zhang	Oct 2015	A1
20150297905	Greenhut et al.	Oct 2015	A1
20150297907	Zhang	Oct 2015	A1
20150305637	Greenhut et al.	Oct 2015	A1
20150305638	Zhang	Oct 2015	A1
20150305639	Greenhut et al.	Oct 2015	A1
20150305640	Reinke et al.	Oct 2015	A1
20150305641	Stadler et al.	Oct 2015	A1
20150305642	Reinke et al.	Oct 2015	A1
20150306374	Seifert et al.	Oct 2015	A1
20150306375	Marshall et al.	Oct 2015	A1
20150306406	Crutchfield et al.	Oct 2015	A1
20150306407	Crutchfield et al.	Oct 2015	A1
20150306408	Greenhut et al.	Oct 2015	A1
20150321016	O'Brien et al.	Nov 2015	A1
20150328459	Chin et al.	Nov 2015	A1
20160015322	Anderson et al.	Jan 2016	A1
20160023000	Cho et al.	Jan 2016	A1
20160030757	Jacobson	Feb 2016	A1
20160033177	Barot et al.	Feb 2016	A1
20160038742	Stahmann et al.	Feb 2016	A1
20160059022	Stahmann et al.	Mar 2016	A1
20160101291	Jaax et al.	Apr 2016	A1
20160121127	Klimovitch et al.	May 2016	A1
20160121128	Fishier et al.	May 2016	A1
20160121129	Persson et al.	May 2016	A1
20160213919	Suwito et al.	Jul 2016	A1
20160213937	Reinke et al.	Jul 2016	A1
20160213939	Carney et al.	Jul 2016	A1
20160228026	Jackson	Aug 2016	A1
20160317825	Jacobson	Nov 2016	A1
20160367823	Cowan et al.	Dec 2016	A1
20170014629	Ghosh et al.	Jan 2017	A1
20170035315	Jackson	Feb 2017	A1
20170043173	Sharma et al.	Feb 2017	A1
20170043174	Greenhut et al.	Feb 2017	A1
20170189681	Anderson	Jul 2017	A1
20170281261	Shuros et al.	Oct 2017	A1
20170281952	Shuros et al.	Oct 2017	A1
20170281953	Min et al.	Oct 2017	A1
20170281955	Maile et al.	Oct 2017	A1
20170312531	Sawchuk	Nov 2017	A1

Foreign Referenced Citations (48)

Number	Date	Country
2009231721	Oct 2009	AU
2008279789	Oct 2011	AU
2008329620	May 2014	AU
2014203793	Jul 2014	AU
1003904	Jan 1977	CA
2679413	Sep 2008	CA
202933393	May 2013	CN
0362611	Apr 1990	EP
503823	Sep 1992	EP
1702648	Sep 2006	EP
1904166	Jun 2011	EP
2433675	Jan 2013	EP
2441491	Jan 2013	EP
2452721	Nov 2013	EP
1948296	Jan 2014	EP
2662113	Jan 2014	EP
2471452	Dec 2014	EP
2760541	May 2016	EP
2833966	May 2016	EP
2398556	Aug 2016	EP
2000051373	Feb 2000	JP
2002502640	Jan 2002	JP
2004512105	Apr 2004	JP
2005508208	Mar 2005	JP
2005245215	Sep 2005	JP
2008540040	Nov 2008	JP
5199867	Feb 2013	JP
8500202	Jan 1995	WO
9636134	Nov 1996	WO
9724981	Jul 1997	WO
9826840	Jun 1998	WO
9939767	Aug 1999	WO
0234330	Jan 2003	WO
02098282	May 2003	WO
2005000206	Apr 2005	WO
2005042089	May 2005	WO
2006065394	Jun 2006	WO
2006086435	Aug 2006	WO
2006113659	Oct 2006	WO
2006124833	May 2007	WO
2007075974	Jul 2007	WO
2009006531	Jan 2009	WO
2012054102	Apr 2012	WO
2013080038	Jun 2013	WO
2013098644	Aug 2013	WO
2013184787	Dec 2013	WO
2014120769	Aug 2014	WO
2017044904	Mar 2017	WO

Non-Patent Literature Citations (7)

Entry
US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)
Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.
Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering,vol. 60(8): 2067-2079, 2013.
Wegmüller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated Jan. 29, 2016, 15 pages.
Spickler et al., “Totally Self-Contained Intracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(3&4): 324-331, 1970.
“Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter,” Nanostim Leadless Pacemakers, pp. 1-28, 2013.

Related Publications (1)

	Number	Date	Country
	20180140851 A1	May 2018	US

Provisional Applications (1)

	Number	Date	Country
	62424918	Nov 2016	US

Wireless re-charge of an implantable medical device

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract